#  @AGatlin_IBD Allison Gatlin Allison Gatlin posts on X about $nvo, $lly, $pfe, eli lilly the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours. ### Engagements: [---] [#](/creator/twitter::1887636869040750592/interactions)  - [--] Week [-----] +396% - [--] Month [------] +180% - [--] Months [------] +26% - [--] Year [------] +47% ### Mentions: [--] [#](/creator/twitter::1887636869040750592/posts_active)  - [--] Week [--] -4.40% - [--] Month [--] +66% - [--] Months [---] +45% - [--] Year [---] +6,650% ### Followers: [---] [#](/creator/twitter::1887636869040750592/followers)  - [--] Week [---] +1.10% - [--] Month [---] +1.30% - [--] Months [---] +31% ### CreatorRank: [---------] [#](/creator/twitter::1887636869040750592/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [finance](/list/finance) [cryptocurrencies](/list/cryptocurrencies) [currencies](/list/currencies) [countries](/list/countries) [travel destinations](/list/travel-destinations) **Social topic influence** [$nvo](/topic/$nvo), [$lly](/topic/$lly), [$pfe](/topic/$pfe), [eli lilly](/topic/eli-lilly), [$sny](/topic/$sny) #37, [$rhhby](/topic/$rhhby), [$mrk](/topic/$mrk), [company](/topic/company), [$hims](/topic/$hims), [$bsx](/topic/$bsx) **Top accounts mentioned or mentioned by** [@thehill](/creator/undefined) [@ibdinvestors](/creator/undefined) [@llcooljosh22](/creator/undefined) [@agatlinibd](/creator/undefined) [@ibdalexis](/creator/undefined) [@ibdagatlin](/creator/undefined) [@bryansmithrisi](/creator/undefined) **Top assets mentioned** [Novo-Nordisk (NVO)](/topic/$nvo) [Eli Lilly and Company (LLY)](/topic/$lly) [Pfizer, Inc. (PFE)](/topic/$pfe) [Synthetify (SNY)](/topic/$sny) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Basilisk (BSX)](/topic/$bsx) [AbbVie Inc (ABBV)](/topic/$abbv) [AstraZeneca PLC (AZN)](/topic/$azn) [Sanofi (SNY)](/topic/sanofi) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Moderna Inc (MRNA)](/topic/$mrna) [Johnson & Johnson (JNJ)](/topic/$jnj) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Amgen, Inc. (AMGN)](/topic/$amgn) [Boston Scientific Corporation (BSX)](/topic/boston-scientific) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Novartis AG (NVS)](/topic/$nvs) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Medpace Holdings, Inc. Common Stock (MEDP)](/topic/$medp) [Measurable Data Token (MDT)](/topic/$mdt) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [GSK plc (GSK)](/topic/$gsk) [Intuitive Surgical, Inc. (ISRG)](/topic/$isrg) [Arcblock (ABT)](/topic/$abt) [Metsera, Inc. (MTSR)](/topic/$mtsr) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Exact Sciences Corp (EXAS)](/topic/$exas) [Insulet, Corp. (PODD)](/topic/$podd) [Novavax Inc (NVAX)](/topic/$nvax) [Protagonist Therapeutics, Inc (PTGX)](/topic/$ptgx) [DexCom, Inc. (DXCM)](/topic/$dxcm) [Incyte Corporation (INCY)](/topic/$incy) [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [Medtronic PLC (MDT)](/topic/medtronic) [Zoetis Inc (ZTS)](/topic/$zts) [Travere Therapeutics, Inc. Common Stock (TVTX)](/topic/$tvtx) [Ventyx Biosciences, Inc. (VTYX)](/topic/$vtyx) [Stryker Corporation (SYK)](/topic/$syk) [Natera, Inc. Common Stock (NTRA)](/topic/$ntra) [Guardant Health, Inc. Common Stock (GH)](/topic/$gh) [Danaher Corporation (DHR)](/topic/$dhr) [ADMA Biologics, Inc. (ADMA)](/topic/$adma) [Exelixis Inc (EXEL)](/topic/$exel) [CVS Health Corp (CVS)](/topic/cvs) [Biogen Inc (BIIB)](/topic/$biib) [Insmed, Inc. (INSM)](/topic/$insm) [Vertex Protocol (VRTX)](/topic/$vrtx) [Liquidia Corporation Common Stock (LQDA)](/topic/$lqda) [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Edwards Lifesciences Corp (EW)](/topic/$ew) [Abbott Laboratories (ABT)](/topic/abbott-laboratories) [Alkermes Inc. plc (ALKS)](/topic/$alks) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)](/topic/$teva) ### Top Social Posts Top posts by engagements in the last [--] hours "$EW beat fourth-quarter expectations largely on the back of a 12% beat for its TMMT business. The TAVR division is Edwards' biggest. Sales topped $1 billion" [X Link](https://x.com/AGatlin_IBD/status/1889784373295054892) 2025-02-12T21:11Z [--] followers, [--] engagements "$HIMS has been on something of a rollercoaster over the last week after the FDA determined semaglutide is no longer in shortage. Here's how the compounder is moving ahead. $NVO $LLY https://www.investors.com/news/technology/hims-stock-hims-hers-health-semaglutide-shortage/ https://www.investors.com/news/technology/hims-stock-hims-hers-health-semaglutide-shortage/" [X Link](https://x.com/AGatlin_IBD/status/1895496271055708555) 2025-02-28T15:28Z [--] followers, [---] engagements "$TGTX which was just added to @IBDinvestors' Leaderboard is on the rise after the company issued a bullish first-quarter outlook. The company makes Briumvi a treatment for relapsing MS. $RHHBY $NVS https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-briumvi-sales-q4-2024/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-briumvi-sales-q4-2024/" [X Link](https://x.com/AGatlin_IBD/status/1896603586941092238) 2025-03-03T16:48Z [--] followers, [---] engagements "$BHVN is under pressure for the second day running after its drug BHV-7000 missed its mark in bipolar mania. But the company says the mechanism is most likely to work in depression and epilepsy. https://www.investors.com/news/technology/biohaven-stock-two-day-fall-bipolar-mania-igg-degrader/ https://www.investors.com/news/technology/biohaven-stock-two-day-fall-bipolar-mania-igg-degrader/" [X Link](https://x.com/AGatlin_IBD/status/1896985008948338690) 2025-03-04T18:04Z [--] followers, [---] engagements "$ILMN is down around 40% over the past month after China added it to its "unreliable entity list." Now the country has banned its imports. https://www.investors.com/news/technology/illumina-stock-china-ban-trump-tariffs/ https://www.investors.com/news/technology/illumina-stock-china-ban-trump-tariffs/" [X Link](https://x.com/AGatlin_IBD/status/1896985322174742750) 2025-03-04T18:05Z [--] followers, [---] engagements "$NVO slashed the price of Wegovy to $499 a month on its new direct-to-consumer website NovoCare. The move follows the FDA's decision that semaglutide is no longer in shortage. $HIMS stock already under pressure fell again. https://www.investors.com/news/technology/novo-nordisk-wegovy-price-cut-hims-stock/ https://www.investors.com/news/technology/novo-nordisk-wegovy-price-cut-hims-stock/" [X Link](https://x.com/AGatlin_IBD/status/1897336661983555668) 2025-03-05T17:21Z [--] followers, [---] engagements "$MRNA has surged by double digits this week helped by executives purchasing stock. But other news has been more mixed. $PFE $BNTX $GSK https://www.investors.com/news/technology/moderna-stock-executives-buy-shares/ https://www.investors.com/news/technology/moderna-stock-executives-buy-shares/" [X Link](https://x.com/AGatlin_IBD/status/1898068236526404003) 2025-03-07T17:48Z [--] followers, [---] engagements "$PTGX broke out after its plaque psoriasis drug developed with $JNJ beat out $BMY's Sotyktu in a head-to-head study. Next up Johnson & Johnson is planning a study against its own Stelara. $ABBV https://www.investors.com/news/technology/protagonist-therapeutics-bristol-myers-squibb-plaque-psoriasis/ https://www.investors.com/news/technology/protagonist-therapeutics-bristol-myers-squibb-plaque-psoriasis/" [X Link](https://x.com/AGatlin_IBD/status/1899119663402951166) 2025-03-10T15:26Z [--] followers, [---] engagements "$NVO's CagriSema appeared similar to $LLY's Zepbound in a Phase [--] study. CagriSema mimics GLP-1 and amylin while Zepbound targets GLP-1 and GIPR. Novo is down more than 8%. https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-cagrisema-zepbound/ https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-cagrisema-zepbound/" [X Link](https://x.com/AGatlin_IBD/status/1899120315047047543) 2025-03-10T15:29Z [---] followers, [---] engagements "$DXCM slumped to a four-month low after the company received a warning letter from the FDA tied to a pair of manufacturing site inspections last year. https://www.investors.com/news/technology/dexcom-stock-fda-warning-letter/ https://www.investors.com/news/technology/dexcom-stock-fda-warning-letter/" [X Link](https://x.com/AGatlin_IBD/status/1899142156532502997) 2025-03-10T16:55Z [--] followers, [---] engagements "$VKTX slumped after signing a manufacturing deal for its weight-loss drug. Why one analyst says it's still a possible takeover candidate. $LLY $NVO https://www.investors.com/news/technology/viking-therapeutics-stock-cordenpharma-deal/ https://www.investors.com/news/technology/viking-therapeutics-stock-cordenpharma-deal/" [X Link](https://x.com/AGatlin_IBD/status/1899481979726221563) 2025-03-11T15:26Z [--] followers, [---] engagements "$RHHBY rose about 4% after inking a deal to co-develop and co-commercialize Zealand Pharma's amylin-based obesity drug. $NVO $LLY $AZN $ABBV https://www.investors.com/news/technology/roche-zealand-pharma-weight-loss-drug-novo-nordisk-cagrisema/ https://www.investors.com/news/technology/roche-zealand-pharma-weight-loss-drug-novo-nordisk-cagrisema/" [X Link](https://x.com/AGatlin_IBD/status/1899916214258024749) 2025-03-12T20:11Z [---] followers, [---] engagements "$INCY posted disappointing results for its HS treatment. One analyst says the drug a JAK1 inhibitor looks viable but not competitive with TNF or IL-17 blockers. https://www.investors.com/news/technology/incyte-stock-hs-treatment-study/ https://www.investors.com/news/technology/incyte-stock-hs-treatment-study/" [X Link](https://x.com/AGatlin_IBD/status/1901642861432435092) 2025-03-17T14:32Z [---] followers, [--] engagements "$SRPT tumbled after a patient died following treatment with Elevidys. Analysts say the move is overdone. $RGNX $SLDB https://www.investors.com/news/technology/sarepta-stock-sarepta-therapeutics-elevidys-gene-therapy-death/ https://www.investors.com/news/technology/sarepta-stock-sarepta-therapeutics-elevidys-gene-therapy-death/" [X Link](https://x.com/AGatlin_IBD/status/1902036169157906680) 2025-03-18T16:35Z [--] followers, [---] engagements "$ROIV and $IMVT put out promising results for their IgG-lowering drug batoclimab in patients with myasthenia gravis and CIDP. Here's why they won't seek approval. https://www.investors.com/news/technology/roivant-sciences-immunovant-batoclimab-imvt-1402/ https://www.investors.com/news/technology/roivant-sciences-immunovant-batoclimab-imvt-1402/" [X Link](https://x.com/AGatlin_IBD/status/1902402924447170594) 2025-03-19T16:52Z [---] followers, [---] engagements "$GILD is under pressure on reports HHS could cut funding for HIV prevention. More than two-thirds of Gilead's [----] sales came from its HIV drugs. https://www.investors.com/news/technology/gilead-stock-hiv-prevention-funding/ https://www.investors.com/news/technology/gilead-stock-hiv-prevention-funding/" [X Link](https://x.com/AGatlin_IBD/status/1902403145247928608) 2025-03-19T16:53Z [--] followers, [--] engagements "$ALNY is setting up a battle with $PFE and $BBIO after winning FDA approval for the first gene silencer to treat ATTR cardiomyopathy. Its Amvuttra costs almost double Pfizer's Vyndaqel and BridgeBio's Attruby. https://www.investors.com/news/technology/alnylam-stock-amvuttra-approval-cardiomyopathy-pfizer-bridgebio/ https://www.investors.com/news/technology/alnylam-stock-amvuttra-approval-cardiomyopathy-pfizer-bridgebio/" [X Link](https://x.com/AGatlin_IBD/status/1903101774946316512) 2025-03-21T15:09Z [--] followers, [---] engagements "$NVO dropped after signing a license deal for a triple agonist being developed for weight loss and diabetes among other conditions. $LLY is also working on its triple agonist retatrutide. https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-the-united-laboratories-international/ https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-the-united-laboratories-international/" [X Link](https://x.com/AGatlin_IBD/status/1904214988753141967) 2025-03-24T16:53Z [--] followers, [---] engagements "The FDA is now expected to make an approval decision on subcutaneous Keytruda in mid-September. The decision could help $MRK maintain some of its Keytruda sales which are expected to drop markedly starting in [----]. https://www.investors.com/news/technology/merck-stock-subcutaneous-keytruda-fda-decision-date/ https://www.investors.com/news/technology/merck-stock-subcutaneous-keytruda-fda-decision-date/" [X Link](https://x.com/AGatlin_IBD/status/1905292358729466297) 2025-03-27T16:14Z [---] followers, [--] engagements "$SLNO surged into a breakout after the company won FDA approval for a drug that treats excessive hunger associated with Prader-Willi syndrome. $AARD also got a boost on the news. https://www.investors.com/news/technology/biotech-stock-soleno-therapeutics-prader-willi-approval/ https://www.investors.com/news/technology/biotech-stock-soleno-therapeutics-prader-willi-approval/" [X Link](https://x.com/AGatlin_IBD/status/1905292541202661835) 2025-03-27T16:15Z [---] followers, [---] engagements "$NVO signed another licensing deal for a weight-loss drug. $LXRX's drug blocks a protein tied to fat accumulation and energy balance. This follows a deal earlier in the week for a triple agonist focused on GLP-1 GIPR and glucagon. https://www.investors.com/news/technology/novo-nordisk-lexicon-pharmaceuticals-obesity-treatment/ https://www.investors.com/news/technology/novo-nordisk-lexicon-pharmaceuticals-obesity-treatment/" [X Link](https://x.com/AGatlin_IBD/status/1905658293575454982) 2025-03-28T16:28Z [---] followers, [---] engagements "$JNJ tumbled after a judge in Texas tossed out its bankruptcy case after finding irregularities in how Johnson & Johnson collected votes from the claimants in its talc lawsuits. https://www.investors.com/news/technology/johnson-johnson-stock-bankruptcy-talc-lawsuits/ https://www.investors.com/news/technology/johnson-johnson-stock-bankruptcy-talc-lawsuits/" [X Link](https://x.com/AGatlin_IBD/status/1907096815318823177) 2025-04-01T15:44Z [---] followers, [---] engagements "$LLY put out a statement following news from $HIMS that it's now selling Zepbound on its telehealth platform. Lilly says it has no affiliation with Hims. "Zepbound can be prescribed by any licensed healthcare professional" a company spokesperson said. https://www.investors.com/news/technology/hims-stock-eli-lilly-weight-loss-drug-zepbound/ https://www.investors.com/news/technology/hims-stock-eli-lilly-weight-loss-drug-zepbound/" [X Link](https://x.com/AGatlin_IBD/status/1907215741797204299) 2025-04-01T23:37Z [---] followers, [---] engagements "$TGTX rallied Wednesday after $RHHBY said a higher dose of intravenous Ocrevus didn't slow progression to disability for patients with relapsing MS. TG's Briumvi is a key rival to Ocrevus after growing rapidly in its second year on the market. https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-drug-ocrevus-briumvi/ https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-drug-ocrevus-briumvi/" [X Link](https://x.com/AGatlin_IBD/status/1907494429851783462) 2025-04-02T18:04Z [---] followers, [----] engagements "$SRPT falls after $RHHBY says the EMA put a clinical hold on studies on Elevidys following a patient's death" [X Link](https://x.com/AGatlin_IBD/status/1907546502425092504) 2025-04-02T21:31Z [---] followers, [---] engagements "$SRPT tumbled after officials in Europe put studies of its gene therapy Elevidys on hold after a teenager in the U.S. died following treatment. https://www.investors.com/news/technology/sarepta-stock-european-medicines-agency-gene-therapy-hold/ https://www.investors.com/news/technology/sarepta-stock-european-medicines-agency-gene-therapy-hold/" [X Link](https://x.com/AGatlin_IBD/status/1907895166771540416) 2025-04-03T20:37Z [---] followers, [---] engagements "DGX was @IBDinvestors' #SOTD. Though the market is risky Quest Diagnostics shares bounced off their 50-day line on Thursday helped by a recent court ruling. $LH https://www.investors.com/research/ibd-stock-of-the-day/quest-diagnostics-tariff-sell-off-texas-ruling-pama/ https://www.investors.com/research/ibd-stock-of-the-day/quest-diagnostics-tariff-sell-off-texas-ruling-pama/" [X Link](https://x.com/AGatlin_IBD/status/1907895442005962876) 2025-04-03T20:38Z [---] followers, [---] engagements "$LLY and $NVO slide late Friday after CMS finalizes several key policies but excludes coverage of obesity drugs. RFK Jr. the new HHS secretary has criticized weight-loss drugs and spoken in favor of non-pharmaceutical interventions. https://www.investors.com/news/technology/eli-lilly-stock-novo-nordisk-stock-weight-loss-drugs-medicare/ https://www.investors.com/news/technology/eli-lilly-stock-novo-nordisk-stock-weight-loss-drugs-medicare/" [X Link](https://x.com/AGatlin_IBD/status/1908291022292963341) 2025-04-04T22:50Z [---] followers, [---] engagements "Trump announced "major" tariffs will be coming soon for pharmaceuticals -- sending drug stocks into a tailspin. $AZN $MRK $BMY $ABBV $NVS $NVO $LLY $AMGN https://www.investors.com/news/technology/dow-jones-sp-500-pharma-names-slammed-as-new-trump-tariffs-target-drug-imports/ https://www.investors.com/news/technology/dow-jones-sp-500-pharma-names-slammed-as-new-trump-tariffs-target-drug-imports/" [X Link](https://x.com/AGatlin_IBD/status/1910015398533115991) 2025-04-09T17:02Z [---] followers, [---] engagements "The Trump administration says the 90-day tariffs delay doesn't apply to sectoral tariffs meaning tariffs on drug imports could still be coming. S&P [---] and Dow Jones names took another bath. $MRK $PFE $ABBV $AMGN $GILD https://www.investors.com/news/technology/trump-tariffs-pharmaceutical-stocks/ https://www.investors.com/news/technology/trump-tariffs-pharmaceutical-stocks/" [X Link](https://x.com/AGatlin_IBD/status/1910386508135125453) 2025-04-10T17:36Z [---] followers, [---] engagements "$ARGX wins a "best-case scenario" for its blockbuster drug Vyvgart. Analysts say this should expand access especially in earlier line of therapy. https://www.investors.com/news/technology/argenx-stock-at-home-prefilled-syringe-vyvgart-hytrulo/ https://www.investors.com/news/technology/argenx-stock-at-home-prefilled-syringe-vyvgart-hytrulo/" [X Link](https://x.com/AGatlin_IBD/status/1910723404803567832) 2025-04-11T15:55Z [---] followers, [---] engagements "$JNJ flexes its financial "bicep" by raising its sales guidance and hiking its dividend despite broader market malaise. $LEGN $SYK $ZBH $BSX https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q1-2025/ https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q1-2025/" [X Link](https://x.com/AGatlin_IBD/status/1912155630623662407) 2025-04-15T14:46Z [---] followers, [---] engagements "My A1 story this week focuses on the minimal residual disease testing market -- a booming area of diagnostics that promises to find cancer relapses earlier than ever before. $NTRA $PSNL $VCYT $EXAS $GH https://www.investors.com/news/technology/guardant-health-natera-exact-sciences-blood-tests-mrd-cancer-testing/ https://www.investors.com/news/technology/guardant-health-natera-exact-sciences-blood-tests-mrd-cancer-testing/" [X Link](https://x.com/AGatlin_IBD/status/1912921088922890534) 2025-04-17T17:28Z [---] followers, [---] engagements "Yes this is an important point. $NVO is also developing a weight-loss pill called amycretin but $LLY remains well in the lead. Good story by @AGatlin_IBD that explains today's surge in Eli Lilly and just as importantly the 7% slide in Novo Nordisk. $LLY $NVO https://t.co/cZJ0AMMHHB Good story by @AGatlin_IBD that explains today's surge in Eli Lilly and just as importantly the 7% slide in Novo Nordisk. $LLY $NVO https://t.co/cZJ0AMMHHB" [X Link](https://x.com/AGatlin_IBD/status/1912927988590448659) 2025-04-17T17:55Z [---] followers, [---] engagements "The earnings bonanza is here. While $DHR and $DGX surged on their first-quarter reports -- with one looking like a bona fide "safe haven" -- $MEDP hit the bricks on another bookings miss" [X Link](https://x.com/AGatlin_IBD/status/1914710040365183005) 2025-04-22T15:57Z [---] followers, [---] engagements "Also this morning $NVO confirmed it filed for approval of oral semaglutide for weight loss "earlier this year." This helps Novo take the lead from $LLY in the race to launch a weight-loss pill. Notably $PFE dropped its leading drug danuglipron earlier this month" [X Link](https://x.com/AGatlin_IBD/status/1914710439990010041) 2025-04-22T15:58Z [---] followers, [---] engagements "ICYMI: $BMY skidded after its schizophrenia drug failed to make a statistically significant difference as an adjunctive treatment. Bristol Myers spent $14 billion to acquire Karuna which initially developed Cobenfy (then KarXT). https://www.investors.com/news/technology/bristol-myers-squibb-cobenfy-adjunctive-treatment-schizophrenia/ https://www.investors.com/news/technology/bristol-myers-squibb-cobenfy-adjunctive-treatment-schizophrenia/" [X Link](https://x.com/AGatlin_IBD/status/1914861179337666666) 2025-04-23T01:57Z [---] followers, [---] engagements "$BNTX surged after $SMMT and Akeso reported promising results for their PD-1- and VEGF-blocking drug ivonescimab. $MRK is also working in this area through a licensing deal. https://www.investors.com/news/technology/biontech-stock-summit-therapeutics-merck-keytruda-anti-vegf/ https://www.investors.com/news/technology/biontech-stock-summit-therapeutics-merck-keytruda-anti-vegf/" [X Link](https://x.com/AGatlin_IBD/status/1915059901312721140) 2025-04-23T15:07Z [---] followers, [---] engagements "$ISRG reversed course Wednesday after investors digested the company's cautious [----] outlook. Late Tuesday the robotic surgery company said the impact of additional tariffs "could be material." https://www.investors.com/news/technology/intuitive-surgical-stock-tariffs-2025/ https://www.investors.com/news/technology/intuitive-surgical-stock-tariffs-2025/" [X Link](https://x.com/AGatlin_IBD/status/1915060217760407909) 2025-04-23T15:08Z [---] followers, [--] engagements "IBD #SOTD $BSX is eyeing two potential entries after a bullish first-quarter report that included a guidance boost. https://www.investors.com/research/ibd-stock-of-the-day/boston-scientific-earnings-q1-2025-double-bottom-base/ https://www.investors.com/research/ibd-stock-of-the-day/boston-scientific-earnings-q1-2025-double-bottom-base/" [X Link](https://x.com/AGatlin_IBD/status/1915464518634766737) 2025-04-24T17:55Z [---] followers, [--] engagements "On the earnings front #pharma names $BMY $RHHBY $SNY and $MRK reported their first-quarter earnings. Bristol Myers beat but shares slipped. Sanofi was mixed while Roche came in ahead. Merck is still facing struggles with Gardasil" [X Link](https://x.com/AGatlin_IBD/status/1915464772876992841) 2025-04-24T17:56Z [---] followers, [---] engagements "$ADMA the No. [--] IBD [--] stock surged after winning FDA approval for a new production process that it expects to yield 20% more immunoglobulin than the previous process. https://www.investors.com/news/technology/adma-stock-adma-biologics-new-yield-process-approval/ https://www.investors.com/news/technology/adma-stock-adma-biologics-new-yield-process-approval/" [X Link](https://x.com/AGatlin_IBD/status/1916880143580045527) 2025-04-28T15:40Z [---] followers, [---] engagements "$HIMS catapulted after signing a deal to sell $NVO's Wegovy on its platform. https://www.investors.com/news/technology/hims-stock-novo-nordisk-deal-wegovy/ https://www.investors.com/news/technology/hims-stock-novo-nordisk-deal-wegovy/" [X Link](https://x.com/AGatlin_IBD/status/1917268901601100070) 2025-04-29T17:25Z [---] followers, [---] engagements "$NVO blamed "unlawful compounding" of its GLP-1 drugs for the decision to cut its [----] sales outlook. Wegovy and Ozempic sales came in mixed with the weight-loss drug missing forecasts though the diabetes med beat. https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q1-2025/ https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q1-2025/" [X Link](https://x.com/AGatlin_IBD/status/1920145769073345009) 2025-05-07T15:56Z [---] followers, [---] engagements "$ARGX's Vyvgart beat first-quarter sales expectations. So why did shares tumble https://www.investors.com/news/technology/argenx-stock-argenx-earnings-q1-2025/ https://www.investors.com/news/technology/argenx-stock-argenx-earnings-q1-2025/" [X Link](https://x.com/AGatlin_IBD/status/1920507146170409286) 2025-05-08T15:52Z [---] followers, [---] engagements "$ADMA plummeted after its first-quarter sales and profit missed expectations. But the company raised its sales outlook for [----] and [----]. https://www.investors.com/news/technology/adma-stock-adma-biologics-earnings-q1-2025/ https://www.investors.com/news/technology/adma-stock-adma-biologics-earnings-q1-2025/" [X Link](https://x.com/AGatlin_IBD/status/1920541042606006412) 2025-05-08T18:07Z [---] followers, [---] engagements "$PODD broke out and rocketed above the 5% buy zone on its strong earnings report. The company is beginning to make gains in the T2D market. https://www.investors.com/news/technology/insulet-stock-insulet-earnings-q1-2025/ https://www.investors.com/news/technology/insulet-stock-insulet-earnings-q1-2025/" [X Link](https://x.com/AGatlin_IBD/status/1920886746566246501) 2025-05-09T17:01Z [---] followers, [---] engagements "ICYMI: $EXEL rocketed to a record high after obliterating first-quarter expectations and raising its full-year guidance by $100 million. https://www.investors.com/news/technology/exelixis-stock-exelixis-earnings-q1-2025/ https://www.investors.com/news/technology/exelixis-stock-exelixis-earnings-q1-2025/" [X Link](https://x.com/AGatlin_IBD/status/1922695384519815566) 2025-05-14T16:47Z [---] followers, [---] engagements "$NVO inked another obesity deal Wednesday sending $SEPN shares flying. They will focus on developing four GPCR-targeting drugs in combination with the usual suspects in weight loss: GLP-1 GIP and glucagon receptors. https://www.investors.com/news/technology/novo-nordisk-obesity-deal-septerna-gpcr/ https://www.investors.com/news/technology/novo-nordisk-obesity-deal-septerna-gpcr/" [X Link](https://x.com/AGatlin_IBD/status/1922695666360275415) 2025-05-14T16:49Z [---] followers, [---] engagements "$ISRG CEO Gary Guthart announced his plan to step down and assume the board chair role. He will be succeeded by Dave Rosa who has been with Intuitive Surgical for nearly three decades. https://www.investors.com/news/technology/intuitive-surgical-stock-ceo-transition-gary-guthart-dave-rosa/ https://www.investors.com/news/technology/intuitive-surgical-stock-ceo-transition-gary-guthart-dave-rosa/" [X Link](https://x.com/AGatlin_IBD/status/1923073815090749887) 2025-05-15T17:51Z [---] followers, [---] engagements "$BMRN is buying $INZY for $270 million. The deal bolsters BioMarin's enzyme replacement therapy business. https://www.investors.com/news/technology/biomarin-inozyme-acquisition-enzyme-replacement-therapy-ert/ https://www.investors.com/news/technology/biomarin-inozyme-acquisition-enzyme-replacement-therapy-ert/" [X Link](https://x.com/AGatlin_IBD/status/1923422895272767685) 2025-05-16T16:58Z [---] followers, [---] engagements "The biggest pharma news of the day though is probably the ousting of $NVO's CEO amid a steep stock decline and increasing competition for its weight-loss drug. $LLY $AMGN $VKTX $AZN $RHHBY https://www.investors.com/news/technology/novo-nordisk-stock-ceo-transition-eli-lilly-weight-loss-drugs/ https://www.investors.com/news/technology/novo-nordisk-stock-ceo-transition-eli-lilly-weight-loss-drugs/" [X Link](https://x.com/AGatlin_IBD/status/1923423152190726611) 2025-05-16T16:59Z [---] followers, [---] engagements "$MRNA reversed its recent rally after the company pulled its application for a combo Covid/flu shot. The news come a day after the FDA put out a new framework for how it will approve Covid shots going forward. https://www.investors.com/news/technology/moderna-stock-covid-flu-combination-shot/ https://www.investors.com/news/technology/moderna-stock-covid-flu-combination-shot/" [X Link](https://x.com/AGatlin_IBD/status/1925225924313723206) 2025-05-21T16:23Z [---] followers, [--] engagements "Here's how the FDA will analyze the effectiveness of Covid vaccines in the future: $PFE $MRNA $BNTX $NVAX https://www.investors.com/news/technology/moderna-vaccine-stocks-fda-covid-vaccine-approvals/ https://www.investors.com/news/technology/moderna-vaccine-stocks-fda-covid-vaccine-approvals/" [X Link](https://x.com/AGatlin_IBD/status/1925226102278041790) 2025-05-21T16:24Z [---] followers, [--] engagements "$MDT announced plans to spin off its nearly $3 billion a year diabetes business. Once the spinoff completes potentially via an IPO the new company will be the only to have CGMs and insulin pumps. $ABT $DXCM $TNDM $PODD https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q4-2025/ https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q4-2025/" [X Link](https://x.com/AGatlin_IBD/status/1925227634964803852) 2025-05-21T16:30Z [---] followers, [---] engagements "$NVO is losing steam to $LLY in the battle for weight-loss leadership. But Novo is inking deals left and right (including with $HIMS) Wegovy won $CVS' Caremark position and Novo could be first with an obesity pill. Can it reverse its fortunes" [X Link](https://x.com/AGatlin_IBD/status/1928122359870890111) 2025-05-29T16:12Z [---] followers, [---] engagements "$REGN and $SNY slumped after their experimental COPD drug showed mixed results -- topping the bar for effectiveness in one study and showing "almost no benefit" in a second an RBC analyst said. https://www.investors.com/news/technology/regeneron-stock-sanofi-stock-copd-treatment-failure/ https://www.investors.com/news/technology/regeneron-stock-sanofi-stock-copd-treatment-failure/" [X Link](https://x.com/AGatlin_IBD/status/1928495693364162716) 2025-05-30T16:56Z [---] followers, [---] engagements "$SMMT crashed after its anti-PD-1/VEGF bispecific missed the bar for overall survival in a highly watched study. The results could bode well for $MRK's Keytruda a top-selling PD-1 used in combination with chemo for numerous cancer types" [X Link](https://x.com/AGatlin_IBD/status/1928495995794444609) 2025-05-30T16:57Z [---] followers, [---] engagements "$MLTX catapulted on a rumored $3 billion takeover offer from $MRK. One analyst says $5 billion makes more sense and another says I&T deals tend to nab 70%-plus premiums. https://www.investors.com/news/technology/biotech-stock-moonlake-immunotherapeutics-takeover-merck/ https://www.investors.com/news/technology/biotech-stock-moonlake-immunotherapeutics-takeover-merck/" [X Link](https://x.com/AGatlin_IBD/status/1929929890243231916) 2025-06-03T15:55Z [---] followers, [---] engagements "ICYMI: I wrote yesterday about $AZN's efforts in cancer treatment. The company unveiled promising results at #ASCO2025 for drugs that could treat forms of breast and gastric cancer. https://www.investors.com/news/technology/astrazeneca-azn-breast-cancer-treatment-asco/ https://www.investors.com/news/technology/astrazeneca-azn-breast-cancer-treatment-asco/" [X Link](https://x.com/AGatlin_IBD/status/1929930825275191760) 2025-06-03T15:58Z [---] followers, [--] engagements "There's a new twist in $REGN's bid to buy 23andMe. https://www.investors.com/news/technology/23andme-former-ceo-anne-wojcicki-regeneron-pharmaceuticals/ https://www.investors.com/news/technology/23andme-former-ceo-anne-wojcicki-regeneron-pharmaceuticals/" [X Link](https://x.com/AGatlin_IBD/status/1930686460870738273) 2025-06-05T18:01Z [---] followers, [---] engagements "$ADA25 is coming. Here's what investors are looking for from $AMGN's MariTide. $LLY $NVO https://www.investors.com/news/technology/amgen-maritide-weight-loss-drug-ada-2025/ https://www.investors.com/news/technology/amgen-maritide-weight-loss-drug-ada-2025/" [X Link](https://x.com/AGatlin_IBD/status/1931048412532879566) 2025-06-06T17:59Z [---] followers, [---] engagements "$MTSR stock jumped -- as high as 28% -- after the company reported promising results for its amylin-focused obesity treatment. $LLY $NVO $ABBV https://www.investors.com/news/technology/metsera-weight-loss-drug-amylin/ https://www.investors.com/news/technology/metsera-weight-loss-drug-amylin/" [X Link](https://x.com/AGatlin_IBD/status/1932123223673704450) 2025-06-09T17:10Z [---] followers, [---] engagements "$MRNA is under pressure after HHS fired all [--] members of the CDC's ACIP. $PFE reversed higher while other stocks were mixed. https://www.investors.com/news/technology/vaccine-stocks-rfk-jr-cdc-acip/ https://www.investors.com/news/technology/vaccine-stocks-rfk-jr-cdc-acip/" [X Link](https://x.com/AGatlin_IBD/status/1932452883833696320) 2025-06-10T15:00Z [---] followers, [---] engagements "$SRPT plummeted after a second patient died following treatment with DMD gene therapy Elevidys. The boy was [--] years old and non-ambulatory but analysts say this could affect uptake among ambulatory patients as well. https://www.investors.com/news/technology/sarepta-stock-plummets-gene-therapy-recipient-dies/ https://www.investors.com/news/technology/sarepta-stock-plummets-gene-therapy-recipient-dies/" [X Link](https://x.com/AGatlin_IBD/status/1934663659378364667) 2025-06-16T17:25Z [---] followers, [---] engagements "The New America this week takes a look at $HIMS which is making waves in the weight-loss space after signing a deal to bundle a Hims & Hers membership with $NVO's Wegovy. https://www.investors.com/news/technology/hims-stock-hims-health-obesity-drugs/ https://www.investors.com/news/technology/hims-stock-hims-health-obesity-drugs/" [X Link](https://x.com/AGatlin_IBD/status/1936091481418481975) 2025-06-20T15:59Z [---] followers, [---] engagements "$NVO and $HIMS took their feud public Monday after Novo Nordisk scrapped its deal with Hims & Hers over concerns about compounded semaglutide. Hims though says Novo was pressuring its sales team to push patients to Wegovy over other options" [X Link](https://x.com/AGatlin_IBD/status/1937248474225082577) 2025-06-23T20:36Z [---] followers, [---] engagements "Read on for the latest: https://www.investors.com/news/technology/hims-stock-novo-nordisk-ends-deal-wegovy-knockoffs-compounded-semaglutide/ https://www.investors.com/news/technology/hims-stock-novo-nordisk-ends-deal-wegovy-knockoffs-compounded-semaglutide/" [X Link](https://x.com/AGatlin_IBD/status/1937248541786906861) 2025-06-23T20:36Z [---] followers, [--] engagements "$EXEL surged on promising results for its next-generation drug in patients with metastatic colon cancer. https://www.investors.com/news/technology/exelixis-stock-next-generation-cancer-drug-colon-cancer/ https://www.investors.com/news/technology/exelixis-stock-next-generation-cancer-drug-colon-cancer/" [X Link](https://x.com/AGatlin_IBD/status/1937248738365620565) 2025-06-23T20:37Z [---] followers, [---] engagements "$BIIB stock is flat but reported promising results for its next-generation SMA drug. If approved it could be a once-yearly treatment vs. the four loading doses and maintenance doses every four months for Spinraza. https://www.investors.com/news/technology/biogen-next-generation-spinraza-spinal-muscular-atrophy-treatment/ https://www.investors.com/news/technology/biogen-next-generation-spinraza-spinal-muscular-atrophy-treatment/" [X Link](https://x.com/AGatlin_IBD/status/1937910266249056401) 2025-06-25T16:26Z [---] followers, [---] engagements "The FDA said Wednesday it's investigating the two patient deaths following treatment with $SRPT's Elevidys. Sarepta stock dropped again. https://www.investors.com/news/technology/sarepta-stock-elevidys-deaths-fda-investigation/ https://www.investors.com/news/technology/sarepta-stock-elevidys-deaths-fda-investigation/" [X Link](https://x.com/AGatlin_IBD/status/1937931330895085829) 2025-06-25T17:50Z [---] followers, [---] engagements "$VKTX is enrolling its Phase [--] studies for obesity candidate VK2735. Two analysts are impressed with the company's strategy. https://www.investors.com/news/technology/viking-therapeutics-stock-weight-loss-drugs-phase-3-testing/ https://www.investors.com/news/technology/viking-therapeutics-stock-weight-loss-drugs-phase-3-testing/" [X Link](https://x.com/AGatlin_IBD/status/1937953388983161196) 2025-06-25T19:17Z [---] followers, [---] engagements "$GILD and $EXAS rose after the Supreme Court shot down a challenge to a key ACA provision. https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeztugo-supreme-court-decision/ https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeztugo-supreme-court-decision/" [X Link](https://x.com/AGatlin_IBD/status/1938677482728915069) 2025-06-27T19:15Z [---] followers, [---] engagements "$MRNA rose moderately after the company unveiled late-stage results for its flu shot. The results could be telling for the company's Covid/flu combination. https://www.investors.com/news/technology/moderna-stock-flu-shot-phase-3/ https://www.investors.com/news/technology/moderna-stock-flu-shot-phase-3/" [X Link](https://x.com/AGatlin_IBD/status/1939743953022329288) 2025-06-30T17:52Z [---] followers, [---] engagements "$PTGX just announced it will move a triple agonist -- targeting GLP-1 GIPR and the glucagon receptor -- into clinical testing. This is similar to $LLY's retatrutide. https://www.investors.com/news/technology/protagonist-therapeutics-obesity-treatment-eli-lilly-retatrutide/ https://www.investors.com/news/technology/protagonist-therapeutics-obesity-treatment-eli-lilly-retatrutide/" [X Link](https://x.com/AGatlin_IBD/status/1939778562699272302) 2025-06-30T20:10Z [---] followers, [---] engagements "$MRK announces $10 billion takeover of $VRNA which makes Ohtuvayre a treatment for COPD. https://www.investors.com/news/technology/verona-pharma-merck-takeover/ https://www.investors.com/news/technology/verona-pharma-merck-takeover/" [X Link](https://x.com/AGatlin_IBD/status/1943006131154210943) 2025-07-09T17:55Z [---] followers, [---] engagements "$RYTM surged to a record high on promising test results for a drug that would treat a form obesity. https://www.investors.com/news/technology/rhythm-pharmaceuticals-stock-record-high-obesity-results/ https://www.investors.com/news/technology/rhythm-pharmaceuticals-stock-record-high-obesity-results/" [X Link](https://x.com/AGatlin_IBD/status/1943006253057458248) 2025-07-09T17:56Z [---] followers, [---] engagements "$JNJ easily beat second-quarter expectations and raised its outlook for the year. But the Dow Jones health giant's report is also promising for $SYK $MDT and $BSX. Here's why: https://www.investors.com/news/technology/johnson-johnson-stock-j-j-earnings-q2-205/ https://www.investors.com/news/technology/johnson-johnson-stock-j-j-earnings-q2-205/" [X Link](https://x.com/AGatlin_IBD/status/1945524284404744210) 2025-07-16T16:41Z [---] followers, [---] engagements "My I&T feature this week takes a look at $INSM which is on the cusp of an FDA decision for its brensocatib a potential treatment for a chronic lung disease. But that's just the tip of the iceberg says CEO Will Lewis. https://www.investors.com/news/technology/insmed-stock-tpip-brensocatib-arikayce/ https://www.investors.com/news/technology/insmed-stock-tpip-brensocatib-arikayce/" [X Link](https://x.com/AGatlin_IBD/status/1948426054244110746) 2025-07-24T16:52Z [---] followers, [----] engagements "In earnings news $ZTS $HIMS and $VRTX all took their hits on Tuesday. Zoetis was rattled by its arthritis drug Librela while investors are now questioning Hims' growth expectations. Vertex meanwhile faced two pain drug setbacks" [X Link](https://x.com/AGatlin_IBD/status/1952833596475019320) 2025-08-05T20:46Z [---] followers, [---] engagements "Read on: Zoetis: Hims: Vertex: https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q2-2025/ https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q2-2025/ https://www.investors.com/news/technology/zoetis-stock-zoetis-earnings-q2-205/ https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q2-2025/ https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q2-2025/ https://www.investors.com/news/technology/zoetis-stock-zoetis-earnings-q2-205/" [X Link](https://x.com/AGatlin_IBD/status/1952833756890329105) 2025-08-05T20:47Z [---] followers, [---] engagements "$LLY crumbled after its obesity pill orforglipron missed expectations in a 72-week study. The results hammered Eli Lilly shares and sent $VKTX and $NVO higher. $GPCR has reversed lower more recently however. https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q2-2025/ https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q2-2025/" [X Link](https://x.com/AGatlin_IBD/status/1953502741852045532) 2025-08-07T17:05Z [---] followers, [---] engagements "$EXAS is under pressure after signing a licensing deal for Freenome's blood-based CRC test. Analysts debate the merits of the deal. https://www.investors.com/news/technology/exact-sciences-stock-exact-sciences-earnings-q2-2025-freenome-blood-test/ https://www.investors.com/news/technology/exact-sciences-stock-exact-sciences-earnings-q2-2025-freenome-blood-test/" [X Link](https://x.com/AGatlin_IBD/status/1953502866846474357) 2025-08-07T17:05Z [---] followers, [---] engagements "$PODD beat second-quarter expectations and raised its outlook yet again. The company is still in the early innings of winning business in the type [--] diabetes space. https://www.investors.com/news/technology/insulet-stock-insulet-earnings-q2-2025/ https://www.investors.com/news/technology/insulet-stock-insulet-earnings-q2-2025/" [X Link](https://x.com/AGatlin_IBD/status/1953503014594945102) 2025-08-07T17:06Z [---] followers, [---] engagements "2/2 I should have done more work at the outset. The story has now been updated with additional context. $LQDA https://www.investors.com/news/technology/liquidia-stock-liquidia-earnings-q2-2025/ https://www.investors.com/news/technology/liquidia-stock-liquidia-earnings-q2-2025/" [X Link](https://x.com/AGatlin_IBD/status/1955353524084281530) 2025-08-12T19:39Z [---] followers, [----] engagements "$ARWR pulled back after $SRPT liquified its stake in the biotech company. One analyst says the deal is a win-win allowing Sarepta to bolster its cash runway while also allowing Arrowhead to repurchase its shares in a non-dilutive way. https://www.investors.com/news/technology/sarepta-therapeutics-arrowhead-pharmaceuticals-stake/ https://www.investors.com/news/technology/sarepta-therapeutics-arrowhead-pharmaceuticals-stake/" [X Link](https://x.com/AGatlin_IBD/status/1956024350030643710) 2025-08-14T16:05Z [---] followers, [---] engagements "$LLY is hiking its list price on Mounjaro in the UK in response to Trump's Most Favored Nation executive order. https://www.investors.com/news/technology/eli-lilly-uk-list-price-mounjaro-most-favored-nation-drug-prices/ https://www.investors.com/news/technology/eli-lilly-uk-list-price-mounjaro-most-favored-nation-drug-prices/" [X Link](https://x.com/AGatlin_IBD/status/1956043913061654881) 2025-08-14T17:23Z [---] followers, [---] engagements "$MDT has a new activist investor. Here's how the new investor is shaking things up. https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q1-2026/ https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q1-2026/" [X Link](https://x.com/AGatlin_IBD/status/1957897296810479746) 2025-08-19T20:07Z [---] followers, [---] engagements "IBD #SOTD $PODD broke out following its strong second-quarter report earlier this month. Momentum is continuing in the type [--] diabetes space. https://www.investors.com/research/ibd-stock-of-the-day/insulet-stock-breaks-out-omnipod-sales/ https://www.investors.com/research/ibd-stock-of-the-day/insulet-stock-breaks-out-omnipod-sales/" [X Link](https://x.com/AGatlin_IBD/status/1957897572216889574) 2025-08-19T20:08Z [---] followers, [---] engagements "IBD #SOTD $BSX is flashing several early buy signals after its "dynamic duo" helped drive a second-quarter beat-and-raise. https://www.investors.com/research/ibd-stock-of-the-day/boston-scientific-stock-breaks-out/ https://www.investors.com/research/ibd-stock-of-the-day/boston-scientific-stock-breaks-out/" [X Link](https://x.com/AGatlin_IBD/status/1958258638021435557) 2025-08-20T20:03Z [---] followers, [---] engagements "$GILD dipped after $CVS said it wouldn't add Yeztugo the twice-a-year shot to its drug coverage list for now. Yeztugo goes for $28000 a year before insurance making it more expensive than other PrEP drugs. https://www.investors.com/news/technology/gilead-stock-hiv-prevention-yeztugo-cvs-health/ https://www.investors.com/news/technology/gilead-stock-hiv-prevention-yeztugo-cvs-health/" [X Link](https://x.com/AGatlin_IBD/status/1958579805131350338) 2025-08-21T17:19Z [---] followers, [---] engagements "$GILD won approval in Europe for its twice-a-year shot to prevent HIV. The drug just faced a setback in the U.S. however. https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeytuo-yeztugo/ https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeytuo-yeztugo/" [X Link](https://x.com/AGatlin_IBD/status/1960371015239761980) 2025-08-26T15:57Z [---] followers, [---] engagements "$LLY said Tuesday it will soon ask for approval of its weight-loss pill on the back of promising results in patients with type [--] diabetes. $NVO and $VKTX slipped on the news. https://www.investors.com/news/technology/eli-lilly-weight-loss-pill-viking-therapeutics-novo-nordisk/ https://www.investors.com/news/technology/eli-lilly-weight-loss-pill-viking-therapeutics-novo-nordisk/" [X Link](https://x.com/AGatlin_IBD/status/1960371142398456147) 2025-08-26T15:57Z [---] followers, [---] engagements "RFK Jr. made good on his promise to end Covid vaccine mandates. $BNTX fell while $PFE $MRNA and $NVAX climbed in response. https://www.investors.com/news/technology/biontech-stock-fda-approval-covid-vaccine-rfk-vaccine-mandates/ https://www.investors.com/news/technology/biontech-stock-fda-approval-covid-vaccine-rfk-vaccine-mandates/" [X Link](https://x.com/AGatlin_IBD/status/1960813705576202250) 2025-08-27T21:16Z [---] followers, [---] engagements "RFK Jr. is on thin ice with the Senate following a grilling Thursday over vaccine policies in the U.S. $MRNA $PFE $BNTX $NVAX https://www.investors.com/news/technology/covid-vaccines-donald-trump-pfizer-moderna/ https://www.investors.com/news/technology/covid-vaccines-donald-trump-pfizer-moderna/" [X Link](https://x.com/AGatlin_IBD/status/1964012080731771065) 2025-09-05T17:05Z [---] followers, [---] engagements "When $HIMS knocked off Wegovy it didn't just anger $NVO. It lit a fire beneath the beleaguered telehealth industry which was still limping away from the Covid pandemic. My A1 for the week: https://www.investors.com/news/technology/telehealth-industry-hims-stock/ https://www.investors.com/news/technology/telehealth-industry-hims-stock/" [X Link](https://x.com/AGatlin_IBD/status/1969025928467464508) 2025-09-19T13:08Z [---] followers, [----] engagements "ACIP voted to end the universal Covid vaccine recommendation but were split on whether to require prescriptions. Ultimately the latter failed. $PFE $MRNA $BNTX $NVAX" [X Link](https://x.com/AGatlin_IBD/status/1969121005076467732) 2025-09-19T19:26Z [---] followers, [---] engagements "ICYMI: On Friday the FDA approved subcutaneous Keytruda. It will take just two minutes to administer vs. [--] minutes for the IV formulation. $MRK https://www.investors.com/news/technology/merck-subcutaneous-keytruda-approved/ https://www.investors.com/news/technology/merck-subcutaneous-keytruda-approved/" [X Link](https://x.com/AGatlin_IBD/status/1970173830246060342) 2025-09-22T17:10Z [---] followers, [---] engagements "$TEM initially flew higher but shares have settled to a sub-2% gain after the FDA cleared the company's new RNA-based assay for investigating cancer. https://www.investors.com/news/technology/tempus-ai-stock-record-high-rna-sequencing-device/ https://www.investors.com/news/technology/tempus-ai-stock-record-high-rna-sequencing-device/" [X Link](https://x.com/AGatlin_IBD/status/1970174007874932750) 2025-09-22T17:11Z [---] followers, [---] engagements "The FDA declined to approve $SRRK's SMA drug citing issues at the Catalent fill-finish facility in Indiana. But the stock has come back from steep premarket gains with analysts noting this is likely a few months' delay. https://www.investors.com/news/technology/scholar-rock-stock-catalent-sma-drug/ https://www.investors.com/news/technology/scholar-rock-stock-catalent-sma-drug/" [X Link](https://x.com/AGatlin_IBD/status/1970510265574924437) 2025-09-23T15:27Z [---] followers, [---] engagements "President Donald Trump's plan to lower U.S. drug prices is facing its first big test: compliance. Here's what we know as rumors fly that the White House will soon make a drug-pricing announcement. https://www.investors.com/news/technology/most-favored-nation-drug-prices/ https://www.investors.com/news/technology/most-favored-nation-drug-prices/" [X Link](https://x.com/AGatlin_IBD/status/1973033314018865539) 2025-09-30T14:32Z [---] followers, [---] engagements "ICYMI: Here's what we know about TrumpRx how it will affect drugmakers and whether it will benefit patients. $PFE $LLY $BMY $ABBV https://www.investors.com/news/technology/most-favored-nation-drug-prices/ https://www.investors.com/news/technology/most-favored-nation-drug-prices/" [X Link](https://x.com/AGatlin_IBD/status/1973459766363185239) 2025-10-01T18:47Z [---] followers, [---] engagements "$AMGN is the latest to join in launching AmgenNow to make cholesterol drug Repatha available at a lower price. It will cost $239 a month which is roughly a 60% discount to its list price. https://www.investors.com/news/technology/most-favored-nation-drug-prices/ https://www.investors.com/news/technology/most-favored-nation-drug-prices/" [X Link](https://x.com/AGatlin_IBD/status/1975221845785038906) 2025-10-06T15:29Z [---] followers, [---] engagements "Earnings season kicked off for pharmaceuticals today with bellwether $JNJ. Sales and EPS beat forecasts but shares fell on a surprise spinoff. https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q3-2025/ https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q3-2025/" [X Link](https://x.com/AGatlin_IBD/status/1978127186725900537) 2025-10-14T15:54Z [---] followers, [---] engagements "This week's New America takes a look at $ARQT an IBD [--] stock focused on its "pipeline in a product" a skin disease treatment that takes on various concentrations and two formulations. https://www.investors.com/research/the-new-america/arcutis-biotherapeutics-arcutis-stock-zoryve/ https://www.investors.com/research/the-new-america/arcutis-biotherapeutics-arcutis-stock-zoryve/" [X Link](https://x.com/AGatlin_IBD/status/1905658514371952675) 2025-03-28T16:29Z [---] followers, [---] engagements "$AZN said its experimental PCSK9 blocker lowered LDL cholesterol by nearly 51% when added to statins. That outperformed rival pills from $MRK and $NAMS but AstraZeneca stock fell in line with broader pharma stocks. https://www.investors.com/news/technology/astrazeneca-stock-cholesterol-treatment-pcsk9-oral/ https://www.investors.com/news/technology/astrazeneca-stock-cholesterol-treatment-pcsk9-oral/" [X Link](https://x.com/AGatlin_IBD/status/1906744342485615071) 2025-03-31T16:24Z [---] followers, [---] engagements "$NVS won FDA approval for its IgA nephropathy drug Vanrafia. It comes without a black box warnings or a REMS. But analysts say $TVTX's Filspari which does have those measures isn't struggling to gain traction. https://www.investors.com/news/technology/novartis-stock-iga-nephropathy-approval-travere-therapeutics/ https://www.investors.com/news/technology/novartis-stock-iga-nephropathy-approval-travere-therapeutics/" [X Link](https://x.com/AGatlin_IBD/status/1907894854538903588) 2025-04-03T20:35Z [---] followers, [---] engagements "$DXCM surged after the FDA cleared its new G7 [--] Day CGM. The company touts the longest wear time at [----] days (which includes a 12-hour grace period to swap out devices). $ABT $MDT https://www.investors.com/news/technology/dexcom-stock-fda-clearance-g7-15-days/ https://www.investors.com/news/technology/dexcom-stock-fda-clearance-g7-15-days/" [X Link](https://x.com/AGatlin_IBD/status/1910351037791187449) 2025-04-10T15:15Z [---] followers, [---] engagements "It's been a busy earnings morning on the biopharma side. $AZN and $PFE reported mixed earnings -- both beat profits views but missed sales estimates. $NVS scored a beat-and-raise but $REGN took a hit on light Eylea sales" [X Link](https://x.com/AGatlin_IBD/status/1917268435563594013) 2025-04-29T17:23Z [---] followers, [---] engagements "Novartis: AstraZeneca: Pfizer: Regeneron: https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q1-2025/ https://www.investors.com/news/technology/pfizer-stock-pfizer-earnings-q1-2025/ https://www.investors.com/news/technology/astrazeneca-stock-astrazeneca-earnings-q1-2025/ https://www.investors.com/news/technology/novartis-stock-novartis-earnings-q1-2025/ https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q1-2025/ https://www.investors.com/news/technology/pfizer-stock-pfizer-earnings-q1-2025/" [X Link](https://x.com/AGatlin_IBD/status/1917268608645837043) 2025-04-29T17:23Z [---] followers, [---] engagements "The CMS draft guidance had some potential bad news for $HALO. Shares plunged by double digits in early Tuesday trades. https://www.investors.com/news/technology/halozyme-therapeutics-medicare-inflation-reduction-act-hyaluronidase-enhanze/ https://www.investors.com/news/technology/halozyme-therapeutics-medicare-inflation-reduction-act-hyaluronidase-enhanze/" [X Link](https://x.com/AGatlin_IBD/status/1922316710964543612) 2025-05-13T15:43Z [---] followers, [---] engagements "The wonderful @IBD_Alexis put together a fantastic video explainer on the MRD market focusing on the efforts by $EXAS $GH and $NTRA. It follows a story I wrote for A1 earlier this year about the massive market for liquid biopsies. https://www.investors.com/ibd-videos/videos/inside-the-multibillion-dollar-cancer-detection-market https://www.investors.com/ibd-videos/videos/inside-the-multibillion-dollar-cancer-detection-market" [X Link](https://x.com/AGatlin_IBD/status/1922775877219160520) 2025-05-14T22:07Z [---] followers, [---] engagements "IBD [--] stock $TVTX nosedived after the FDA decided to hold an advisory committee meeting for its drug Filspari ahead of a potential approval in FSGS treatment. It's not the only stock to face that setback this week. https://www.investors.com/news/technology/travere-therapeutics-filspari-fsgs-advisory-committee-meeting/ https://www.investors.com/news/technology/travere-therapeutics-filspari-fsgs-advisory-committee-meeting/" [X Link](https://x.com/AGatlin_IBD/status/1923422769707913289) 2025-05-16T16:58Z [---] followers, [---] engagements "$REGN won the right to buy 23andMe $MEHCQ for $256 million at the bankruptcy auction. The biotech giant says it will maintain 23andMe's consumer genome services. https://www.investors.com/news/technology/23andme-biotech-buyer-regeneron-pharmaceuticals/ https://www.investors.com/news/technology/23andme-biotech-buyer-regeneron-pharmaceuticals/" [X Link](https://x.com/AGatlin_IBD/status/1924485589828763932) 2025-05-19T15:21Z [---] followers, [---] engagements "$BSX said Wednesday it would stop selling its TAVR system after a failed clinical study muddied the path forward for approval. $EW and $MDT jumped. $ABT which was originally in the green is now down slightly. https://www.investors.com/news/technology/edwards-lifesciences-stock-boston-scientific-tavr/ https://www.investors.com/news/technology/edwards-lifesciences-stock-boston-scientific-tavr/" [X Link](https://x.com/AGatlin_IBD/status/1927748173944025507) 2025-05-28T15:25Z [---] followers, [---] engagements "$VEEV surged after the company reported strong fiscal first-quarter earnings. Shares broke out of a consolidation and the RS line hit a new high. https://www.investors.com/news/technology/veeva-stock-veeva-systems-earnings-q1-2026-2/ https://www.investors.com/news/technology/veeva-stock-veeva-systems-earnings-q1-2026-2/" [X Link](https://x.com/AGatlin_IBD/status/1928112970736738786) 2025-05-29T15:35Z [---] followers, [--] engagements "$INSM catapulted and broke out after presenting positive results for its rival to PAH drugs from $UTHR and $LQDA. https://www.investors.com/news/technology/insmed-stock-pah-treatment-united-therapeutics-liquidia/ https://www.investors.com/news/technology/insmed-stock-pah-treatment-united-therapeutics-liquidia/" [X Link](https://x.com/AGatlin_IBD/status/1932453351079522565) 2025-06-10T15:02Z [---] followers, [---] engagements "$SUPN is buying $SAGE after numerous setbacks hammered the biotech stock over the last few years. $BIIB tried to buy it earlier this year but Supernus put together a bigger offer. https://www.investors.com/news/technology/sage-therapeutics-takeover-supernus-pharmaceuticals/ https://www.investors.com/news/technology/sage-therapeutics-takeover-supernus-pharmaceuticals/" [X Link](https://x.com/AGatlin_IBD/status/1934663942451941520) 2025-06-16T17:26Z [---] followers, [---] engagements "$CRMD inked an expanded deal for its DefenCath with a large dialysis organization and raised its sales outlook for the second quarter. $DVA https://www.investors.com/news/technology/cormedix-stock-defencath-large-dialysis-organization/ https://www.investors.com/news/technology/cormedix-stock-defencath-large-dialysis-organization/" [X Link](https://x.com/AGatlin_IBD/status/1937249100908626358) 2025-06-23T20:39Z [---] followers, [---] engagements "$KVUE which is known for brands like Aveeno Band-Aid Listerine and Tylenol yo-yoed after the CEO stepped down amid a strategic review. Kenvue is facing off with Starboard Value an activist investor. https://www.investors.com/news/technology/kenvue-stock-ceo-change-strategic-review/ https://www.investors.com/news/technology/kenvue-stock-ceo-change-strategic-review/" [X Link](https://x.com/AGatlin_IBD/status/1944808199074537915) 2025-07-14T17:16Z [---] followers, [---] engagements "ICYMI: $EW is benefitting after $BSX exited the TAVR market. Boston Scientific though continues to rise on excitement for its cardiovascular portfolio. https://www.investors.com/news/technology/edwards-lifesciences-stock-edwards-lifesciences-earnings-q2-2025/ https://www.investors.com/news/technology/edwards-lifesciences-stock-edwards-lifesciences-earnings-q2-2025/" [X Link](https://x.com/AGatlin_IBD/status/1948844387662004506) 2025-07-25T20:34Z [---] followers, [---] engagements "$TGTX is a top 3% biotech stock. But shares crumbled after the company's second-quarter report. Here's why. https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q2-2025/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q2-2025/" [X Link](https://x.com/AGatlin_IBD/status/1952393995633774652) 2025-08-04T15:39Z [---] followers, [---] engagements "$AXGN plunged after the FDA delayed the review date for its nerve graft product. But one analyst isn't sweating it. https://www.investors.com/news/technology/axogen-stock-fda-delay-avance-nerve-graft/ https://www.investors.com/news/technology/axogen-stock-fda-delay-avance-nerve-graft/" [X Link](https://x.com/AGatlin_IBD/status/1960030352359203056) 2025-08-25T17:23Z [---] followers, [---] engagements "$DNTH surged Monday on promising results for its generalized myasthenia gravis treatment a potential rival to drugs from $ARGX $AZN and $SNY. Shares ran up markedly ahead of the readout. https://www.investors.com/news/technology/dianthus-therapeutics-stock-argenx-vyvgart/ https://www.investors.com/news/technology/dianthus-therapeutics-stock-argenx-vyvgart/" [X Link](https://x.com/AGatlin_IBD/status/1965146664525795680) 2025-09-08T20:14Z [---] followers, [---] engagements "$CRNX surged after the company won FDA approval for the first new acromegaly drug in decades. Acromegaly is a form of gigantism famously suffered by Andre Rene Roussimoff widely known as "Andre the Giant." https://www.investors.com/news/technology/crinetics-pharmaceuticals-approves-palsonify-acromegaly-treatment/ https://www.investors.com/news/technology/crinetics-pharmaceuticals-approves-palsonify-acromegaly-treatment/" [X Link](https://x.com/AGatlin_IBD/status/1971632619088732204) 2025-09-26T17:47Z [---] followers, [---] engagements "More on the earnings front $ABT came up mixed with sales narrowly missing expectations. One analyst noted FX could have had a role to play there. https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-earnings-q3-2025/ https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-earnings-q3-2025/" [X Link](https://x.com/AGatlin_IBD/status/1978509318677745923) 2025-10-15T17:12Z [---] followers, [---] engagements "$OMER is up triple digits after $NVO agreed to a licensing deal for its potential treatment for rare blood and kidney diseases. https://www.investors.com/news/technology/omeros-stock-novo-nordisk-licensing-deal/ https://www.investors.com/news/technology/omeros-stock-novo-nordisk-licensing-deal/" [X Link](https://x.com/AGatlin_IBD/status/1978509646101983666) 2025-10-15T17:13Z [---] followers, [---] engagements "$HOLX agreed to an $18.3 billion take-private deal. Shares rose last week on rumors Blackstone and TPG bid $16 billion to buy it. https://www.investors.com/news/technology/hologic-blackstone-tpg-take-private-acquisition/ https://www.investors.com/news/technology/hologic-blackstone-tpg-take-private-acquisition/" [X Link](https://x.com/AGatlin_IBD/status/1980685568875827501) 2025-10-21T17:20Z [---] followers, [---] engagements "$DHR surged topping its buy zone on a strong earnings report backed by its bioprocessing division. https://www.investors.com/news/technology/danaher-stock-danaher-earnings-q3-2025/ https://www.investors.com/news/technology/danaher-stock-danaher-earnings-q3-2025/" [X Link](https://x.com/AGatlin_IBD/status/1980685731476787534) 2025-10-21T17:20Z [---] followers, [---] engagements "ICYMI: $ISRG smashed earnings expectations late Tuesday. Shares are up by double digits today helped by the hiked procedure growth guidance for [----]. https://www.investors.com/news/technology/intuitive-surgical-stock-intuitive-surgical-earnings-q3-2025/ https://www.investors.com/news/technology/intuitive-surgical-stock-intuitive-surgical-earnings-q3-2025/" [X Link](https://x.com/AGatlin_IBD/status/1981080180773793973) 2025-10-22T19:28Z [---] followers, [---] engagements "$BSX jumped after one of its key segments posted 63% sales growth. https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q3-2025/ https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q3-2025/" [X Link](https://x.com/AGatlin_IBD/status/1981081370743967928) 2025-10-22T19:33Z [---] followers, [---] engagements "Here's what confused the Street about $ALKS' buyout of $AVDL says one analyst. https://www.investors.com/news/technology/avadel-pharmaceuticals-alkermes-buyout-sleep-disorders/ https://www.investors.com/news/technology/avadel-pharmaceuticals-alkermes-buyout-sleep-disorders/" [X Link](https://x.com/AGatlin_IBD/status/1981081529112465538) 2025-10-22T19:33Z [---] followers, [---] engagements "On the earnings front $MEDP had a strong showing with a massive 1.20x book-to-bill ratio that impressed investors and analysts. The company beat its own forecast for 1.15x. https://www.investors.com/news/technology/medpace-stock-medpace-holdings-earnings-q3-2025/ https://www.investors.com/news/technology/medpace-stock-medpace-holdings-earnings-q3-2025/" [X Link](https://x.com/AGatlin_IBD/status/1981457292991353279) 2025-10-23T20:26Z [---] followers, [---] engagements "$VKTX stock also put up a strong showing after the company said it expects to finish enrolling patients in two Phase [--] obesity treatment studies later this year and early next. https://www.investors.com/news/technology/viking-therapeutics-stock-obesity-treatment-studies/ https://www.investors.com/news/technology/viking-therapeutics-stock-obesity-treatment-studies/" [X Link](https://x.com/AGatlin_IBD/status/1981457491360960952) 2025-10-23T20:27Z [---] followers, [---] engagements "$MTSR says $PFE's claims are "nonsense." The latter is suing Metsera and $NVO over their proposed $6.5 billion deal. Novo swooped in last week widely Pfizer's $4.9 billion deal to buy Metsera an obesity-focused biotech. https://www.investors.com/news/technology/metsera-pfizer-novo-nordisk-takeover-litigation/ https://www.investors.com/news/technology/metsera-pfizer-novo-nordisk-takeover-litigation/" [X Link](https://x.com/AGatlin_IBD/status/1985411494075334826) 2025-11-03T18:19Z [---] followers, [---] engagements "$QURE is under pressure down roughly 50% after the FDA issued unexpected feedback on its gene therapy for Huntington's disease. The news comes less than six weeks after UniQure stock skyrocketed almost 250% on positive test results. https://www.investors.com/news/technology/uniqure-stock-huntingtons-gene-therapy-fda-feedback/ https://www.investors.com/news/technology/uniqure-stock-huntingtons-gene-therapy-fda-feedback/" [X Link](https://x.com/AGatlin_IBD/status/1985411985706570013) 2025-11-03T18:21Z [---] followers, [---] engagements "I got [--] minutes this morning to chat with $NVO's CFO Karsten Munk Knudsen about $MTSR $HIMS $LLY and of course the company's third guidance cut this year. Here's why he says Novo Nordisk's "hyper growth" has stalled. https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q3-2025/ https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q3-2025/" [X Link](https://x.com/AGatlin_IBD/status/1986183089597653277) 2025-11-05T21:25Z [---] followers, [---] engagements "It's been a wild week for the weight-loss drugs segment with $LLY and $NVO inking MFN deals and Novo duking it out with $PFE to buy $MTSR. Earlier this year obesity stocks were in a rut. Now Some of them are telling a different story. https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/ https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/" [X Link](https://x.com/AGatlin_IBD/status/1986930478876950910) 2025-11-07T22:55Z [---] followers, [---] engagements "ICYMI: $MRK and $CRSP unveiled positive results for cholesterol treatments. Merck's is a daily pill while Crispr's would be a one-time gene-editing treatment. https://www.investors.com/news/technology/crispr-stock-intellia-stock-gene-editing-cholesterol-triglycerides-hae/ https://www.investors.com/news/technology/merck-amgen-regeneron-pcsk9-pill-cholesterol-treatment/ https://www.investors.com/news/technology/crispr-stock-intellia-stock-gene-editing-cholesterol-triglycerides-hae/ https://www.investors.com/news/technology/merck-amgen-regeneron-pcsk9-pill-cholesterol-treatment/" [X Link](https://x.com/AGatlin_IBD/status/1987952024642568575) 2025-11-10T18:34Z [---] followers, [---] engagements "$ANAB reversed a recent 70% run after its ulcerative colitis drug failed in midstage testing. One analyst pegged it as having only a 15% chance of succeeding. https://www.investors.com/news/technology/anaptysbio-stock-ulcerative-colitis-treatment-failure/ https://www.investors.com/news/technology/anaptysbio-stock-ulcerative-colitis-treatment-failure/" [X Link](https://x.com/AGatlin_IBD/status/1987952183904469206) 2025-11-10T18:35Z [---] followers, [---] engagements "Meanwhile the battle with $RHHBY and $TGTX continues in multiple sclerosis. TG took the most recent hit. https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-treatment/ https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-treatment/" [X Link](https://x.com/AGatlin_IBD/status/1987952326640853310) 2025-11-10T18:35Z [---] followers, [---] engagements "Also ICYMI: The $PFE and $NVO battle to acquire $MTSR ended on Friday. Here's how it went down: https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-buyout-battle/ https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-buyout-battle/" [X Link](https://x.com/AGatlin_IBD/status/1987952541359902960) 2025-11-10T18:36Z [---] followers, [---] engagements "$COGT is up by triple digits on a first in [--] years development in treating second-line GIST. https://www.investors.com/news/technology/cogent-biosciences-stock-gist-treatment/ https://www.investors.com/news/technology/cogent-biosciences-stock-gist-treatment/" [X Link](https://x.com/AGatlin_IBD/status/1987966741973192982) 2025-11-10T19:33Z [---] followers, [---] engagements "On the M&A and cancer front $JNJ is buying privately held Halda Therapeutics. It's working on oral treatments that could treat a myriad of cancers. https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/ https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/" [X Link](https://x.com/AGatlin_IBD/status/1990551061007118840) 2025-11-17T22:42Z [---] followers, [---] engagements "$NVO lowered the price of its GLP-1 drugs Ozempic and Wegovy on its NovoCare DTC website. The price is lower than what $LLY charges for its rival drugs Mounjaro and Zepbound. https://www.investors.com/news/technology/novo-nordisk-eli-lilly-trumprx-wegovy-ozempic-price-cuts/ https://www.investors.com/news/technology/novo-nordisk-eli-lilly-trumprx-wegovy-ozempic-price-cuts/" [X Link](https://x.com/AGatlin_IBD/status/1990551246496018621) 2025-11-17T22:42Z [---] followers, [---] engagements "My I&T feature this week focuses on $LGND the royalty-focused biotech backer behind $TVTX's Filspari and $MRK's Ohtuvayre. https://www.investors.com/news/technology/ligand-pharmaceuticals-royalty-business-biotech/ https://www.investors.com/news/technology/ligand-pharmaceuticals-royalty-business-biotech/" [X Link](https://x.com/AGatlin_IBD/status/1990848378100674684) 2025-11-18T18:23Z [---] followers, [---] engagements "$MRK said Tuesday sotatercept (branded Winrevair) showed promise in patients with a form of pulmonary hypertension. But the company doesn't seem to be filing with the FDA based on these results. https://www.investors.com/news/technology/merck-stock-pulmonary-hypertension-sotatercept/ https://www.investors.com/news/technology/merck-stock-pulmonary-hypertension-sotatercept/" [X Link](https://x.com/AGatlin_IBD/status/1990848559860928714) 2025-11-18T18:24Z [---] followers, [---] engagements "$MDT broke out of a flat base helped by massive growth for its pulsed field ablation technology. It rivals $BSX in that segment. https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q3-2025-2/ https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q3-2025-2/" [X Link](https://x.com/AGatlin_IBD/status/1990848765431865692) 2025-11-18T18:25Z [---] followers, [---] engagements "Today's IBD #SOTD takes a look at $MEDP which shot higher on its massive book-to-bill beat in the third quarter. But analysts wonder if Medpace is worth its sky-high valuation relative to other CRO stocks. https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-contract-resource-organization-q3-2025/ https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-contract-resource-organization-q3-2025/" [X Link](https://x.com/AGatlin_IBD/status/1990865674483425438) 2025-11-18T19:32Z [---] followers, [---] engagements "While quieter than the $NVO and $PFE dustup over Metsera $ALKS and Lundbeck are continuing to trade bids over $AVDL. Today Alkermes has the "superior proposal." https://www.investors.com/news/technology/alkermes-avadel-pharmaceuticals-buyout-lundbeck/ https://www.investors.com/news/technology/alkermes-avadel-pharmaceuticals-buyout-lundbeck/" [X Link](https://x.com/AGatlin_IBD/status/1991215255930708205) 2025-11-19T18:41Z [---] followers, [---] engagements "$VKTX slumped though the company said it over-enrolled a study of its obesity treatment VK2735. https://www.investors.com/news/technology/viking-therapeutics-stock-enrollment-phase-3-vk2735/ https://www.investors.com/news/technology/viking-therapeutics-stock-enrollment-phase-3-vk2735/" [X Link](https://x.com/AGatlin_IBD/status/1991215586924257536) 2025-11-19T18:42Z [---] followers, [---] engagements "$AGIO plummeted while $FULC surged after Agios said mitapivat missed its goal in a Phase [--] study of patients with sickle cell disease. https://www.investors.com/news/technology/agios-pharmacuticals-stock-sickle-cell-treatment-mitapivat/ https://www.investors.com/news/technology/agios-pharmacuticals-stock-sickle-cell-treatment-mitapivat/" [X Link](https://x.com/AGatlin_IBD/status/1991215771007992123) 2025-11-19T18:43Z [---] followers, [---] engagements "My A1 story this week takes a look at the ADC space or what we've been calling "smart bombs" for cancer in the newsroom. It seems all the big oncology names are in this space including $AZN $GSK $ABBV $RHHBY and others. https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/ https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/" [X Link](https://x.com/AGatlin_IBD/status/1991913827374649416) 2025-11-21T16:57Z [---] followers, [---] engagements "This week's New America feature takes a look at $TVTX which is nearing potential approval of a second condition for its drug Filspari. Filspari treats IgAN but could win the OK to treat another kidney disease FSGS in January. https://www.investors.com/research/the-new-america/travere-therapeutics-stock-kidney-disease-filspari-fsgs/ https://www.investors.com/research/the-new-america/travere-therapeutics-stock-kidney-disease-filspari-fsgs/" [X Link](https://x.com/AGatlin_IBD/status/1993738414114640256) 2025-11-26T17:47Z [---] followers, [---] engagements "In pharma news CMS revealed the negotiated prices for a basket of [--] drugs beginning in [----]. $NVO and $TEVA shares rose while other stocks were more muted. Unrelated $SNY is under pressure after French authorities raided its Paris HQ. https://www.investors.com/news/technology/novo-nordisk-stock-ozempic-wegovy-ira-discounts/ https://www.investors.com/news/technology/novo-nordisk-stock-ozempic-wegovy-ira-discounts/" [X Link](https://x.com/AGatlin_IBD/status/1993738793795703225) 2025-11-26T17:49Z [---] followers, [---] engagements "Sanofi confirmed the tax fraud investigation: https://www.investors.com/news/technology/sanofi-stock-paris-raid-tax-fraud-investigation/ https://www.investors.com/news/technology/sanofi-stock-paris-raid-tax-fraud-investigation/" [X Link](https://x.com/AGatlin_IBD/status/1993738895356571789) 2025-11-26T17:49Z [---] followers, [--] engagements "Our I&T feature is out early this week and takes a look at $BBIO featuring an interview with CEO Neil Kumar. BridgeBio stock has run up by triple digits this year amid several Phase [--] readouts with another in the works. https://www.investors.com/news/technology/bridgebio-pharma-stock-2025/ https://www.investors.com/news/technology/bridgebio-pharma-stock-2025/" [X Link](https://x.com/AGatlin_IBD/status/1995905523141746741) 2025-12-02T17:18Z [---] followers, [---] engagements "$CAPR surged as much as 535% today -- shares are currently up about 340% -- on promising test results for its cell therapy approach to Duchenne muscular dystrophy. This follows a CRL earlier in the fall. https://www.investors.com/news/technology/capricor-stock-duchenne-muscular-dystrophy/ https://www.investors.com/news/technology/capricor-stock-duchenne-muscular-dystrophy/" [X Link](https://x.com/AGatlin_IBD/status/1996296807656378593) 2025-12-03T19:13Z [---] followers, [---] engagements "$RCUS tumbled reversing a winning streak over the past eight months after its $GILD-partnered anti-TIGIT drug failed in upper gastrointestinal cancers. https://www.investors.com/news/technology/arcus-biosciences-gilead-sciences-anti-tigit-failure/ https://www.investors.com/news/technology/arcus-biosciences-gilead-sciences-anti-tigit-failure/" [X Link](https://x.com/AGatlin_IBD/status/1999542482770575509) 2025-12-12T18:10Z [---] followers, [---] engagements "@thehill has a slightly wider camera. I can also see $AMGN and $BMY" [X Link](https://x.com/AGatlin_IBD/status/2002093466051096603) 2025-12-19T19:07Z [---] followers, [--] engagements "@thehill The full list includes $SNY $NVS $RHHBY's Genentech Boehringer Ingelheim $GILD $BMY $GSK $MRK and $AMGN. Trump says that [--] out of [--] of the biggest pharma companies. He says the other [--] have also signed deals including $JNJ" [X Link](https://x.com/AGatlin_IBD/status/2002099907369578722) 2025-12-19T19:33Z [---] followers, [---] engagements "$ARWR followed in the footsteps of $WVE silencing the gene responsible for activin E to improve fat loss. Shares are up by double digits. But one analyst says Wave could have the edge. https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/ https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/" [X Link](https://x.com/AGatlin_IBD/status/2008576275724857353) 2026-01-06T16:27Z [---] followers, [----] engagements "$LLY confirmed its $1.2 billion plan to acquire $VTYX late Wednesday. https://www.investors.com/news/technology/eli-lilly-ventyx-biosciences-ventyx-stock/ https://www.investors.com/news/technology/eli-lilly-ventyx-biosciences-ventyx-stock/" [X Link](https://x.com/AGatlin_IBD/status/2009041392870543421) 2026-01-07T23:16Z [---] followers, [---] engagements "Here's today's #SOTD which focused on $LLY's rally following the initial rumors of the $VTYX deal. https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-ibd-stock-of-the-day-offers-two-entries-on-rumored-buyout-rally/ https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-ibd-stock-of-the-day-offers-two-entries-on-rumored-buyout-rally/" [X Link](https://x.com/AGatlin_IBD/status/2009041513918157002) 2026-01-07T23:16Z [---] followers, [---] engagements "#Biotech stocks made a comeback in the latter half of [----] soaring more than 82% from a low point in April amid a flurry of M&A deals and enthusiasm for strong clinical data. Here's what experts are watching for this year. https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/ https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/" [X Link](https://x.com/AGatlin_IBD/status/2009306902824366263) 2026-01-08T16:51Z [---] followers, [---] engagements "$TVTX was hammered after the company said it just wrapped answering FDA questions ahead of its Jan. [--] PDUFA for Filspari in FSGS. The late FDA request and response could indicate a delay for Filspari. https://www.investors.com/news/technology/travere-therapeutics-stock-fda-review-filspari-fsgs-treatment/ https://www.investors.com/news/technology/travere-therapeutics-stock-fda-review-filspari-fsgs-treatment/" [X Link](https://x.com/AGatlin_IBD/status/2011148931145855063) 2026-01-13T18:50Z [---] followers, [---] engagements "Today's #SOTD takes a look at $MEDP as shares flirt with an early entry. The biotech funding environment looks strong which could benefits CROs. https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-buy-point-biotech-funding/ https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-buy-point-biotech-funding/" [X Link](https://x.com/AGatlin_IBD/status/2011187075601649877) 2026-01-13T21:22Z [---] followers, [---] engagements "$NVO is up 9% at the moment benefitting from a strong first week of Wegovy pill prescriptions. $LLY https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/ https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/" [X Link](https://x.com/AGatlin_IBD/status/2012249386814779833) 2026-01-16T19:43Z [---] followers, [---] engagements "$CGON rocketed as much as 44% on promising results for its $JNJ-rivaling bladder cancer drug. https://www.investors.com/news/technology/cg-oncology-johnson-johnson-bladder-cancer-treatment/ https://www.investors.com/news/technology/cg-oncology-johnson-johnson-bladder-cancer-treatment/" [X Link](https://x.com/AGatlin_IBD/status/1916880249557578093) 2025-04-28T15:40Z [---] followers, [---] engagements "Read more from Neurocrine's report here: Vertex raised the low side of its outlook despite missing Q1 sales calls: Hims is planning to sign more partnerships after the $NVO news last week: https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q1-2025/ https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q1-2025/ https://www.investors.com/news/technology/neurocrine-biosciences-stock-neurocrine-biosciences-earnings-q1-2025/ https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q1-2025/" [X Link](https://x.com/AGatlin_IBD/status/1919794736371478839) 2025-05-06T16:41Z [---] followers, [---] engagements "$JANX is down almost 50% on mixed results for its prostate cancer treatment. But analysts are upbeat saying its drug could eventually be a blockbuster. https://www.investors.com/news/technology/janux-therapeutics-stock-prostate-cancer-treatment/ https://www.investors.com/news/technology/janux-therapeutics-stock-prostate-cancer-treatment/" [X Link](https://x.com/AGatlin_IBD/status/1995905258384736404) 2025-12-02T17:17Z [---] followers, [---] engagements "$ALMS more than doubled today on test results for its plaque psoriasis drug a potential rival to oral meds from $JNJ $PTGX and $TAK. https://www.investors.com/news/technology/alumis-biotech-stock-plaque-psoriasis-treatment/ https://www.investors.com/news/technology/alumis-biotech-stock-plaque-psoriasis-treatment/" [X Link](https://x.com/AGatlin_IBD/status/2008576471749755135) 2026-01-06T16:28Z [---] followers, [---] engagements "$ISRG is under pressure after issuing a lackluster view for [----] procedure growth. $GKOS also took a hit on its guidance. https://www.investors.com/news/technology/intuitive-surgical-stock-robotic-surgery-preannouncement/ https://www.investors.com/news/technology/intuitive-surgical-stock-robotic-surgery-preannouncement/" [X Link](https://x.com/AGatlin_IBD/status/2011480361339855083) 2026-01-14T16:47Z [---] followers, [---] engagements "$CORT surged after its ovarian cancer regimen met the overall survival bar in a late-stage study. https://www.investors.com/news/technology/corcept-therapeutics-ovarian-cancer-relacorilant/ https://www.investors.com/news/technology/corcept-therapeutics-ovarian-cancer-relacorilant/" [X Link](https://x.com/AGatlin_IBD/status/2014389786551976080) 2026-01-22T17:28Z [---] followers, [---] engagements "$NVO's oral Wegovy clocked in at [-----] prescriptions (likely not including NovoCare) in its second week. That's far and away north of the [----] from $LLY's Zepbound in its second week of launch. https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-second-week-launch/ https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-second-week-launch/" [X Link](https://x.com/anyuser/status/2014754311293882681) 2026-01-23T17:37Z [---] followers, [----] engagements "An analyst with RBC says $REGN could soon become acquisitive. The press release reads "more direct" on the potential for business development than it has in the past. $SNY $BAYRY https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/ https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/" [X Link](https://x.com/anyuser/status/2017290426819219479) 2026-01-30T17:34Z [---] followers, [----] engagements "$EWTX and $CYTK diverged Wednesday after Edgewise put out promising results for its HCM drug but noted four patients experienced atrial fibrillation. Analysts were mostly unconcerned noting afib tends to occur in the HCM population" [X Link](https://x.com/AGatlin_IBD/status/1907463085507375312) 2025-04-02T16:00Z [---] followers, [---] engagements "It's important to note Cytokinetics is several years ahead of Edgewise with its PDUFA for aficamten in obstructive HCM scheduled for September. Read on here: https://www.investors.com/news/technology/edgewise-therapeutics-hcm-safety-cytokinetics-aficamten/ https://www.investors.com/news/technology/edgewise-therapeutics-hcm-safety-cytokinetics-aficamten/" [X Link](https://x.com/AGatlin_IBD/status/1907463274695639465) 2025-04-02T16:00Z [---] followers, [---] engagements "Dollar stock $VIGL skyrocketed after $SNY agreed to buy it for $470 million. The deal includes a CVR that brings the total value up to $600 million. https://www.investors.com/news/technology/sanofi-vigil-neuroscience-acquisition/ https://www.investors.com/news/technology/sanofi-vigil-neuroscience-acquisition/" [X Link](https://x.com/AGatlin_IBD/status/1925584152876970097) 2025-05-22T16:06Z [---] followers, [---] engagements "$APGE reversed steep premarket gains despite promising results for its eczema drug a potential twice-yearly shot. The results are comparable to $SNY and $REGN's Dupixent and $LLY's Ebglyss. https://www.investors.com/news/technology/apogee-therapeutics-eczema-shot/ https://www.investors.com/news/technology/apogee-therapeutics-eczema-shot/" [X Link](https://x.com/AGatlin_IBD/status/1942267074707087412) 2025-07-07T16:58Z [---] followers, [---] engagements "Why one analyst says $NVS' $1.4 billion takeover of $TRML just "makes sense." $NVO https://www.investors.com/news/technology/novartis-tourmaline-bio-acquisition/ https://www.investors.com/news/technology/novartis-tourmaline-bio-acquisition/" [X Link](https://x.com/AGatlin_IBD/status/1965423777636028540) 2025-09-09T14:35Z [---] followers, [---] engagements "$PHVS and $KALV surged after Pharvaris reported promising results for its treatment for HAE attacks. https://www.investors.com/news/technology/pharvaris-kalvista-hae-treatment/ https://www.investors.com/news/technology/pharvaris-kalvista-hae-treatment/" [X Link](https://x.com/AGatlin_IBD/status/1996297161341022540) 2025-12-03T19:15Z [---] followers, [---] engagements "$ARGX toppled after stopping a study of Vyvgart in patients with thyroid eye disease. Analyst say the decision isn't a big hit for Vyvgart but could bolster $VRDN. https://www.investors.com/news/technology/argenx-stock-vyvgart-thryoid-eye-disease-viridian/ https://www.investors.com/news/technology/argenx-stock-vyvgart-thryoid-eye-disease-viridian/" [X Link](https://x.com/AGatlin_IBD/status/2000617765225312581) 2025-12-15T17:23Z [---] followers, [---] engagements "#JPM2026 so far has been marked by a slew of preannouncements for the fourth quarter. Here are the winners and losers from day one: $ANY $SRPT $IRTC $DAWN $ANIP https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/ https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/" [X Link](https://x.com/AGatlin_IBD/status/2010782857594355907) 2026-01-12T18:36Z [---] followers, [----] engagements "$RAPT soared after $GSK agreed to buy it for $2.2 billion. Rapt is working on a preventative treatment for food allergies. https://www.investors.com/news/technology/rapt-stock-gsk-buyout/ https://www.investors.com/news/technology/rapt-stock-gsk-buyout/" [X Link](https://x.com/AGatlin_IBD/status/2013679280937427415) 2026-01-20T18:25Z [---] followers, [---] engagements "$SRPT surged on promising three-year results for Elevidys. But analysts are split on whether it will help uptake for the embattled gene therapy. $SLDB $RGNX https://www.investors.com/news/technology/sarepta-stock-three-year-elevidys-test-gene-therapy/ https://www.investors.com/news/technology/sarepta-stock-three-year-elevidys-test-gene-therapy/" [X Link](https://x.com/anyuser/status/2015897486645182502) 2026-01-26T21:19Z [---] followers, [---] engagements "$INMD got a boost after an Israeli news site reported the medical aesthetics company is in advanced talks to be acquired for $1.1 billion. https://www.investors.com/news/technology/inmode-stock-takeover-offer-rumor/ https://www.investors.com/news/technology/inmode-stock-takeover-offer-rumor/" [X Link](https://x.com/anyuser/status/2015897689410466010) 2026-01-26T21:20Z [---] followers, [---] engagements "$LLY issued "assertive" guidance Wednesday well above expectations. Analysts say this helps following $NVO's downbeat outlook on Tuesday. https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q4-2025/ https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q4-2025/" [X Link](https://x.com/anyuser/status/2019095559475265624) 2026-02-04T17:07Z [---] followers, [---] engagements "$NVO continued its two-day plunge Wednesday after the company said it expects sales and operating profit to fall this year. Here's what CFO Karsten Knudsen had to say about the outlook and how oral Wegovy could fit in. $LLY https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q4-2025/ https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q4-2025/" [X Link](https://x.com/anyuser/status/2019097796511690770) 2026-02-04T17:16Z [---] followers, [---] engagements "The biotech industry in China is taking off. My A1 feature this week examines why Big Pharma is taking China seriously -- as a partner and a rival. https://www.investors.com/news/technology/biotech-stocks-china-biotech-competition/ https://www.investors.com/news/technology/biotech-stocks-china-biotech-competition/" [X Link](https://x.com/anyuser/status/2019830856437887279) 2026-02-06T17:49Z [---] followers, [---] engagements "@LLCoolJosh22 Thank you Josh I havent examined $IBRX. Dollar stocks are tricky. We tend to focus on higher-value stocks" [X Link](https://x.com/AGatlin_IBD/status/2020246483350745339) 2026-02-07T21:21Z [---] followers, [---] engagements "$SPRY made a bullish move after reporting its earnings. The company narrowly beat Neffy sales forecasts for [----] though the majority of its revenue came from partnerships and supply agreements. https://www.investors.com/news/technology/ars-pharmaceuticals-stock-earnings-q4-2024/ https://www.investors.com/news/technology/ars-pharmaceuticals-stock-earnings-q4-2024/" [X Link](https://x.com/AGatlin_IBD/status/1902757916089749640) 2025-03-20T16:23Z [---] followers, [--] engagements "An analyst says $BBIO could change the standard of care in achondroplasia causes disproportionate short-limb stature. The company hit its bull case for the Phase [--] study. https://www.investors.com/news/technology/bridgebio-stock-achondroplasia-treatment/ https://www.investors.com/news/technology/bridgebio-stock-achondroplasia-treatment/" [X Link](https://x.com/AGatlin_IBD/status/2022047083965165815) 2026-02-12T20:36Z [---] followers, [----] engagements "$HRMY took a hit after the FDA rejected Wakix as a treatment for idiopathic hypersomnia. The drug missed its primary endpoint in Phase [--] testing but the company was hoping the FDA would look at the totality of its data. https://www.investors.com/news/technology/harmony-biosciences-fda-rejects-wakix-idiopathic-hypersomnia/ https://www.investors.com/news/technology/harmony-biosciences-fda-rejects-wakix-idiopathic-hypersomnia/" [X Link](https://x.com/AGatlin_IBD/status/1892250646436319735) 2025-02-19T16:31Z [---] followers, [---] engagements "I'm playing catch-up after being out of the office for a few days. $HIMS had a mixed Q1 report and shares fell on its light Q2 outlook. $VRTX is also under pressure on a series of setbacks including a pause for its mRNA-based CF drug. $NBIX though saw momentum for Crenessity" [X Link](https://x.com/AGatlin_IBD/status/1919794262067105956) 2025-05-06T16:39Z [---] followers, [---] engagements "I'm back from a weeklong staycation to celebrate my twins' fifth birthday. The morning kicked off with $IDXX shooting higher on its earnings report. The company is tied to the animal-health space. https://www.investors.com/news/technology/idexx-laboratories-stock-idexx-laboratories-earnings-q2-2025/ https://www.investors.com/news/technology/idexx-laboratories-stock-idexx-laboratories-earnings-q2-2025/" [X Link](https://x.com/AGatlin_IBD/status/1952393760857530495) 2025-08-04T15:38Z [---] followers, [---] engagements "In earnings news $TGTX beat expectations and raised its outlook but fell on a caveat that undercut its massive profit beat. $IDXX also topped forecasts and shares broke out to a record high. https://www.investors.com/news/technology/idexx-laboratories-idexx-stock-earnings-q3-2025/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q3-2025/ https://www.investors.com/news/technology/idexx-laboratories-idexx-stock-earnings-q3-2025/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q3-2025/" [X Link](https://x.com/AGatlin_IBD/status/1985411723608658078) 2025-11-03T18:20Z [---] followers, [---] engagements "$BIOA rocketed after the company reported promising results for its NLRP3 blocker a potential cardiovascular treatment and rival to $LLY takeover play $VTYX. https://www.investors.com/news/technology/bioage-labs-bioage-stock-eli-lilly-ventyx-biosciences-nlrp3/ https://www.investors.com/news/technology/bioage-labs-bioage-stock-eli-lilly-ventyx-biosciences-nlrp3/" [X Link](https://x.com/AGatlin_IBD/status/2010782086530261185) 2026-01-12T18:33Z [---] followers, [---] engagements "$ISRG disappointed investors earlier this month with its 13%-15% guidance for [----] procedure growth for da Vinci. But an analyst says it's not all gloom for the robotic surgery stock. https://www.investors.com/news/technology/intuitive-surgical-stock-isrg-earnings-q4-2025/ https://www.investors.com/news/technology/intuitive-surgical-stock-isrg-earnings-q4-2025/" [X Link](https://x.com/AGatlin_IBD/status/2014754087527669930) 2026-01-23T17:36Z [---] followers, [---] engagements "In other earnings news $SNY beat earnings forecasts and Dupixent sales came in ahead though total sales were light. Its key partner $REGN reports tomorrow morning. https://www.investors.com/news/technology/sanofi-stock-sanofi-earnings-q4-2025/ https://www.investors.com/news/technology/sanofi-stock-sanofi-earnings-q4-2025/" [X Link](https://x.com/anyuser/status/2016985857962774871) 2026-01-29T21:24Z [---] followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@AGatlin_IBD Allison Gatlin
Allison Gatlin posts on X about $nvo, $lly, $pfe, eli lilly the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [-----] +396%
- [--] Month [------] +180%
- [--] Months [------] +26%
- [--] Year [------] +47%
Mentions: [--] #
- [--] Week [--] -4.40%
- [--] Month [--] +66%
- [--] Months [---] +45%
- [--] Year [---] +6,650%
Followers: [---] #
- [--] Week [---] +1.10%
- [--] Month [---] +1.30%
- [--] Months [---] +31%
CreatorRank: [---------] #
Social Influence
Social category influence stocks finance cryptocurrencies currencies countries travel destinations
Social topic influence $nvo, $lly, $pfe, eli lilly, $sny #37, $rhhby, $mrk, company, $hims, $bsx
Top accounts mentioned or mentioned by @thehill @ibdinvestors @llcooljosh22 @agatlinibd @ibdalexis @ibdagatlin @bryansmithrisi
Top assets mentioned Novo-Nordisk (NVO) Eli Lilly and Company (LLY) Pfizer, Inc. (PFE) Synthetify (SNY) Merck & Co., Inc. (MRK) Hims & Hers Health, Inc. (HIMS) Basilisk (BSX) AbbVie Inc (ABBV) AstraZeneca PLC (AZN) Sanofi (SNY) Regeneron Pharmaceuticals Inc (REGN) Moderna Inc (MRNA) Johnson & Johnson (JNJ) Sarepta Therapeutics, Inc. (SRPT) Amgen, Inc. (AMGN) Boston Scientific Corporation (BSX) Viking Therapeutics, Inc (VKTX) Novartis AG (NVS) Gilead Sciences, Inc. (GILD) Bristol-Myers Squibb Co (BMY) Medpace Holdings, Inc. Common Stock (MEDP) Measurable Data Token (MDT) TG Therapeutics, Inc. (TGTX) GSK plc (GSK) Intuitive Surgical, Inc. (ISRG) Arcblock (ABT) Metsera, Inc. (MTSR) BridgeBio Pharma, Inc. Common Stock (BBIO) Exact Sciences Corp (EXAS) Insulet, Corp. (PODD) Novavax Inc (NVAX) Protagonist Therapeutics, Inc (PTGX) DexCom, Inc. (DXCM) Incyte Corporation (INCY) Summit Therapeutics Inc. Common Stock (SMMT) Medtronic PLC (MDT) Zoetis Inc (ZTS) Travere Therapeutics, Inc. Common Stock (TVTX) Ventyx Biosciences, Inc. (VTYX) Stryker Corporation (SYK) Natera, Inc. Common Stock (NTRA) Guardant Health, Inc. Common Stock (GH) Danaher Corporation (DHR) ADMA Biologics, Inc. (ADMA) Exelixis Inc (EXEL) CVS Health Corp (CVS) Biogen Inc (BIIB) Insmed, Inc. (INSM) Vertex Protocol (VRTX) Liquidia Corporation Common Stock (LQDA) Arrowhead Research Corporation (ARWR) Edwards Lifesciences Corp (EW) Abbott Laboratories (ABT) Alkermes Inc. plc (ALKS) CRISPR Therapeutics AG (CRSP) Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Top Social Posts
Top posts by engagements in the last [--] hours
"$EW beat fourth-quarter expectations largely on the back of a 12% beat for its TMMT business. The TAVR division is Edwards' biggest. Sales topped $1 billion"
X Link 2025-02-12T21:11Z [--] followers, [--] engagements
"$HIMS has been on something of a rollercoaster over the last week after the FDA determined semaglutide is no longer in shortage. Here's how the compounder is moving ahead. $NVO $LLY https://www.investors.com/news/technology/hims-stock-hims-hers-health-semaglutide-shortage/ https://www.investors.com/news/technology/hims-stock-hims-hers-health-semaglutide-shortage/"
X Link 2025-02-28T15:28Z [--] followers, [---] engagements
"$TGTX which was just added to @IBDinvestors' Leaderboard is on the rise after the company issued a bullish first-quarter outlook. The company makes Briumvi a treatment for relapsing MS. $RHHBY $NVS https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-briumvi-sales-q4-2024/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-briumvi-sales-q4-2024/"
X Link 2025-03-03T16:48Z [--] followers, [---] engagements
"$BHVN is under pressure for the second day running after its drug BHV-7000 missed its mark in bipolar mania. But the company says the mechanism is most likely to work in depression and epilepsy. https://www.investors.com/news/technology/biohaven-stock-two-day-fall-bipolar-mania-igg-degrader/ https://www.investors.com/news/technology/biohaven-stock-two-day-fall-bipolar-mania-igg-degrader/"
X Link 2025-03-04T18:04Z [--] followers, [---] engagements
"$ILMN is down around 40% over the past month after China added it to its "unreliable entity list." Now the country has banned its imports. https://www.investors.com/news/technology/illumina-stock-china-ban-trump-tariffs/ https://www.investors.com/news/technology/illumina-stock-china-ban-trump-tariffs/"
X Link 2025-03-04T18:05Z [--] followers, [---] engagements
"$NVO slashed the price of Wegovy to $499 a month on its new direct-to-consumer website NovoCare. The move follows the FDA's decision that semaglutide is no longer in shortage. $HIMS stock already under pressure fell again. https://www.investors.com/news/technology/novo-nordisk-wegovy-price-cut-hims-stock/ https://www.investors.com/news/technology/novo-nordisk-wegovy-price-cut-hims-stock/"
X Link 2025-03-05T17:21Z [--] followers, [---] engagements
"$MRNA has surged by double digits this week helped by executives purchasing stock. But other news has been more mixed. $PFE $BNTX $GSK https://www.investors.com/news/technology/moderna-stock-executives-buy-shares/ https://www.investors.com/news/technology/moderna-stock-executives-buy-shares/"
X Link 2025-03-07T17:48Z [--] followers, [---] engagements
"$PTGX broke out after its plaque psoriasis drug developed with $JNJ beat out $BMY's Sotyktu in a head-to-head study. Next up Johnson & Johnson is planning a study against its own Stelara. $ABBV https://www.investors.com/news/technology/protagonist-therapeutics-bristol-myers-squibb-plaque-psoriasis/ https://www.investors.com/news/technology/protagonist-therapeutics-bristol-myers-squibb-plaque-psoriasis/"
X Link 2025-03-10T15:26Z [--] followers, [---] engagements
"$NVO's CagriSema appeared similar to $LLY's Zepbound in a Phase [--] study. CagriSema mimics GLP-1 and amylin while Zepbound targets GLP-1 and GIPR. Novo is down more than 8%. https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-cagrisema-zepbound/ https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-cagrisema-zepbound/"
X Link 2025-03-10T15:29Z [---] followers, [---] engagements
"$DXCM slumped to a four-month low after the company received a warning letter from the FDA tied to a pair of manufacturing site inspections last year. https://www.investors.com/news/technology/dexcom-stock-fda-warning-letter/ https://www.investors.com/news/technology/dexcom-stock-fda-warning-letter/"
X Link 2025-03-10T16:55Z [--] followers, [---] engagements
"$VKTX slumped after signing a manufacturing deal for its weight-loss drug. Why one analyst says it's still a possible takeover candidate. $LLY $NVO https://www.investors.com/news/technology/viking-therapeutics-stock-cordenpharma-deal/ https://www.investors.com/news/technology/viking-therapeutics-stock-cordenpharma-deal/"
X Link 2025-03-11T15:26Z [--] followers, [---] engagements
"$RHHBY rose about 4% after inking a deal to co-develop and co-commercialize Zealand Pharma's amylin-based obesity drug. $NVO $LLY $AZN $ABBV https://www.investors.com/news/technology/roche-zealand-pharma-weight-loss-drug-novo-nordisk-cagrisema/ https://www.investors.com/news/technology/roche-zealand-pharma-weight-loss-drug-novo-nordisk-cagrisema/"
X Link 2025-03-12T20:11Z [---] followers, [---] engagements
"$INCY posted disappointing results for its HS treatment. One analyst says the drug a JAK1 inhibitor looks viable but not competitive with TNF or IL-17 blockers. https://www.investors.com/news/technology/incyte-stock-hs-treatment-study/ https://www.investors.com/news/technology/incyte-stock-hs-treatment-study/"
X Link 2025-03-17T14:32Z [---] followers, [--] engagements
"$SRPT tumbled after a patient died following treatment with Elevidys. Analysts say the move is overdone. $RGNX $SLDB https://www.investors.com/news/technology/sarepta-stock-sarepta-therapeutics-elevidys-gene-therapy-death/ https://www.investors.com/news/technology/sarepta-stock-sarepta-therapeutics-elevidys-gene-therapy-death/"
X Link 2025-03-18T16:35Z [--] followers, [---] engagements
"$ROIV and $IMVT put out promising results for their IgG-lowering drug batoclimab in patients with myasthenia gravis and CIDP. Here's why they won't seek approval. https://www.investors.com/news/technology/roivant-sciences-immunovant-batoclimab-imvt-1402/ https://www.investors.com/news/technology/roivant-sciences-immunovant-batoclimab-imvt-1402/"
X Link 2025-03-19T16:52Z [---] followers, [---] engagements
"$GILD is under pressure on reports HHS could cut funding for HIV prevention. More than two-thirds of Gilead's [----] sales came from its HIV drugs. https://www.investors.com/news/technology/gilead-stock-hiv-prevention-funding/ https://www.investors.com/news/technology/gilead-stock-hiv-prevention-funding/"
X Link 2025-03-19T16:53Z [--] followers, [--] engagements
"$ALNY is setting up a battle with $PFE and $BBIO after winning FDA approval for the first gene silencer to treat ATTR cardiomyopathy. Its Amvuttra costs almost double Pfizer's Vyndaqel and BridgeBio's Attruby. https://www.investors.com/news/technology/alnylam-stock-amvuttra-approval-cardiomyopathy-pfizer-bridgebio/ https://www.investors.com/news/technology/alnylam-stock-amvuttra-approval-cardiomyopathy-pfizer-bridgebio/"
X Link 2025-03-21T15:09Z [--] followers, [---] engagements
"$NVO dropped after signing a license deal for a triple agonist being developed for weight loss and diabetes among other conditions. $LLY is also working on its triple agonist retatrutide. https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-the-united-laboratories-international/ https://www.investors.com/news/technology/novo-nordisk-stock-weight-loss-drug-the-united-laboratories-international/"
X Link 2025-03-24T16:53Z [--] followers, [---] engagements
"The FDA is now expected to make an approval decision on subcutaneous Keytruda in mid-September. The decision could help $MRK maintain some of its Keytruda sales which are expected to drop markedly starting in [----]. https://www.investors.com/news/technology/merck-stock-subcutaneous-keytruda-fda-decision-date/ https://www.investors.com/news/technology/merck-stock-subcutaneous-keytruda-fda-decision-date/"
X Link 2025-03-27T16:14Z [---] followers, [--] engagements
"$SLNO surged into a breakout after the company won FDA approval for a drug that treats excessive hunger associated with Prader-Willi syndrome. $AARD also got a boost on the news. https://www.investors.com/news/technology/biotech-stock-soleno-therapeutics-prader-willi-approval/ https://www.investors.com/news/technology/biotech-stock-soleno-therapeutics-prader-willi-approval/"
X Link 2025-03-27T16:15Z [---] followers, [---] engagements
"$NVO signed another licensing deal for a weight-loss drug. $LXRX's drug blocks a protein tied to fat accumulation and energy balance. This follows a deal earlier in the week for a triple agonist focused on GLP-1 GIPR and glucagon. https://www.investors.com/news/technology/novo-nordisk-lexicon-pharmaceuticals-obesity-treatment/ https://www.investors.com/news/technology/novo-nordisk-lexicon-pharmaceuticals-obesity-treatment/"
X Link 2025-03-28T16:28Z [---] followers, [---] engagements
"$JNJ tumbled after a judge in Texas tossed out its bankruptcy case after finding irregularities in how Johnson & Johnson collected votes from the claimants in its talc lawsuits. https://www.investors.com/news/technology/johnson-johnson-stock-bankruptcy-talc-lawsuits/ https://www.investors.com/news/technology/johnson-johnson-stock-bankruptcy-talc-lawsuits/"
X Link 2025-04-01T15:44Z [---] followers, [---] engagements
"$LLY put out a statement following news from $HIMS that it's now selling Zepbound on its telehealth platform. Lilly says it has no affiliation with Hims. "Zepbound can be prescribed by any licensed healthcare professional" a company spokesperson said. https://www.investors.com/news/technology/hims-stock-eli-lilly-weight-loss-drug-zepbound/ https://www.investors.com/news/technology/hims-stock-eli-lilly-weight-loss-drug-zepbound/"
X Link 2025-04-01T23:37Z [---] followers, [---] engagements
"$TGTX rallied Wednesday after $RHHBY said a higher dose of intravenous Ocrevus didn't slow progression to disability for patients with relapsing MS. TG's Briumvi is a key rival to Ocrevus after growing rapidly in its second year on the market. https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-drug-ocrevus-briumvi/ https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-drug-ocrevus-briumvi/"
X Link 2025-04-02T18:04Z [---] followers, [----] engagements
"$SRPT falls after $RHHBY says the EMA put a clinical hold on studies on Elevidys following a patient's death"
X Link 2025-04-02T21:31Z [---] followers, [---] engagements
"$SRPT tumbled after officials in Europe put studies of its gene therapy Elevidys on hold after a teenager in the U.S. died following treatment. https://www.investors.com/news/technology/sarepta-stock-european-medicines-agency-gene-therapy-hold/ https://www.investors.com/news/technology/sarepta-stock-european-medicines-agency-gene-therapy-hold/"
X Link 2025-04-03T20:37Z [---] followers, [---] engagements
"DGX was @IBDinvestors' #SOTD. Though the market is risky Quest Diagnostics shares bounced off their 50-day line on Thursday helped by a recent court ruling. $LH https://www.investors.com/research/ibd-stock-of-the-day/quest-diagnostics-tariff-sell-off-texas-ruling-pama/ https://www.investors.com/research/ibd-stock-of-the-day/quest-diagnostics-tariff-sell-off-texas-ruling-pama/"
X Link 2025-04-03T20:38Z [---] followers, [---] engagements
"$LLY and $NVO slide late Friday after CMS finalizes several key policies but excludes coverage of obesity drugs. RFK Jr. the new HHS secretary has criticized weight-loss drugs and spoken in favor of non-pharmaceutical interventions. https://www.investors.com/news/technology/eli-lilly-stock-novo-nordisk-stock-weight-loss-drugs-medicare/ https://www.investors.com/news/technology/eli-lilly-stock-novo-nordisk-stock-weight-loss-drugs-medicare/"
X Link 2025-04-04T22:50Z [---] followers, [---] engagements
"Trump announced "major" tariffs will be coming soon for pharmaceuticals -- sending drug stocks into a tailspin. $AZN $MRK $BMY $ABBV $NVS $NVO $LLY $AMGN https://www.investors.com/news/technology/dow-jones-sp-500-pharma-names-slammed-as-new-trump-tariffs-target-drug-imports/ https://www.investors.com/news/technology/dow-jones-sp-500-pharma-names-slammed-as-new-trump-tariffs-target-drug-imports/"
X Link 2025-04-09T17:02Z [---] followers, [---] engagements
"The Trump administration says the 90-day tariffs delay doesn't apply to sectoral tariffs meaning tariffs on drug imports could still be coming. S&P [---] and Dow Jones names took another bath. $MRK $PFE $ABBV $AMGN $GILD https://www.investors.com/news/technology/trump-tariffs-pharmaceutical-stocks/ https://www.investors.com/news/technology/trump-tariffs-pharmaceutical-stocks/"
X Link 2025-04-10T17:36Z [---] followers, [---] engagements
"$ARGX wins a "best-case scenario" for its blockbuster drug Vyvgart. Analysts say this should expand access especially in earlier line of therapy. https://www.investors.com/news/technology/argenx-stock-at-home-prefilled-syringe-vyvgart-hytrulo/ https://www.investors.com/news/technology/argenx-stock-at-home-prefilled-syringe-vyvgart-hytrulo/"
X Link 2025-04-11T15:55Z [---] followers, [---] engagements
"$JNJ flexes its financial "bicep" by raising its sales guidance and hiking its dividend despite broader market malaise. $LEGN $SYK $ZBH $BSX https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q1-2025/ https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q1-2025/"
X Link 2025-04-15T14:46Z [---] followers, [---] engagements
"My A1 story this week focuses on the minimal residual disease testing market -- a booming area of diagnostics that promises to find cancer relapses earlier than ever before. $NTRA $PSNL $VCYT $EXAS $GH https://www.investors.com/news/technology/guardant-health-natera-exact-sciences-blood-tests-mrd-cancer-testing/ https://www.investors.com/news/technology/guardant-health-natera-exact-sciences-blood-tests-mrd-cancer-testing/"
X Link 2025-04-17T17:28Z [---] followers, [---] engagements
"Yes this is an important point. $NVO is also developing a weight-loss pill called amycretin but $LLY remains well in the lead. Good story by @AGatlin_IBD that explains today's surge in Eli Lilly and just as importantly the 7% slide in Novo Nordisk. $LLY $NVO https://t.co/cZJ0AMMHHB Good story by @AGatlin_IBD that explains today's surge in Eli Lilly and just as importantly the 7% slide in Novo Nordisk. $LLY $NVO https://t.co/cZJ0AMMHHB"
X Link 2025-04-17T17:55Z [---] followers, [---] engagements
"The earnings bonanza is here. While $DHR and $DGX surged on their first-quarter reports -- with one looking like a bona fide "safe haven" -- $MEDP hit the bricks on another bookings miss"
X Link 2025-04-22T15:57Z [---] followers, [---] engagements
"Also this morning $NVO confirmed it filed for approval of oral semaglutide for weight loss "earlier this year." This helps Novo take the lead from $LLY in the race to launch a weight-loss pill. Notably $PFE dropped its leading drug danuglipron earlier this month"
X Link 2025-04-22T15:58Z [---] followers, [---] engagements
"ICYMI: $BMY skidded after its schizophrenia drug failed to make a statistically significant difference as an adjunctive treatment. Bristol Myers spent $14 billion to acquire Karuna which initially developed Cobenfy (then KarXT). https://www.investors.com/news/technology/bristol-myers-squibb-cobenfy-adjunctive-treatment-schizophrenia/ https://www.investors.com/news/technology/bristol-myers-squibb-cobenfy-adjunctive-treatment-schizophrenia/"
X Link 2025-04-23T01:57Z [---] followers, [---] engagements
"$BNTX surged after $SMMT and Akeso reported promising results for their PD-1- and VEGF-blocking drug ivonescimab. $MRK is also working in this area through a licensing deal. https://www.investors.com/news/technology/biontech-stock-summit-therapeutics-merck-keytruda-anti-vegf/ https://www.investors.com/news/technology/biontech-stock-summit-therapeutics-merck-keytruda-anti-vegf/"
X Link 2025-04-23T15:07Z [---] followers, [---] engagements
"$ISRG reversed course Wednesday after investors digested the company's cautious [----] outlook. Late Tuesday the robotic surgery company said the impact of additional tariffs "could be material." https://www.investors.com/news/technology/intuitive-surgical-stock-tariffs-2025/ https://www.investors.com/news/technology/intuitive-surgical-stock-tariffs-2025/"
X Link 2025-04-23T15:08Z [---] followers, [--] engagements
"IBD #SOTD $BSX is eyeing two potential entries after a bullish first-quarter report that included a guidance boost. https://www.investors.com/research/ibd-stock-of-the-day/boston-scientific-earnings-q1-2025-double-bottom-base/ https://www.investors.com/research/ibd-stock-of-the-day/boston-scientific-earnings-q1-2025-double-bottom-base/"
X Link 2025-04-24T17:55Z [---] followers, [--] engagements
"On the earnings front #pharma names $BMY $RHHBY $SNY and $MRK reported their first-quarter earnings. Bristol Myers beat but shares slipped. Sanofi was mixed while Roche came in ahead. Merck is still facing struggles with Gardasil"
X Link 2025-04-24T17:56Z [---] followers, [---] engagements
"$ADMA the No. [--] IBD [--] stock surged after winning FDA approval for a new production process that it expects to yield 20% more immunoglobulin than the previous process. https://www.investors.com/news/technology/adma-stock-adma-biologics-new-yield-process-approval/ https://www.investors.com/news/technology/adma-stock-adma-biologics-new-yield-process-approval/"
X Link 2025-04-28T15:40Z [---] followers, [---] engagements
"$HIMS catapulted after signing a deal to sell $NVO's Wegovy on its platform. https://www.investors.com/news/technology/hims-stock-novo-nordisk-deal-wegovy/ https://www.investors.com/news/technology/hims-stock-novo-nordisk-deal-wegovy/"
X Link 2025-04-29T17:25Z [---] followers, [---] engagements
"$NVO blamed "unlawful compounding" of its GLP-1 drugs for the decision to cut its [----] sales outlook. Wegovy and Ozempic sales came in mixed with the weight-loss drug missing forecasts though the diabetes med beat. https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q1-2025/ https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q1-2025/"
X Link 2025-05-07T15:56Z [---] followers, [---] engagements
"$ARGX's Vyvgart beat first-quarter sales expectations. So why did shares tumble https://www.investors.com/news/technology/argenx-stock-argenx-earnings-q1-2025/ https://www.investors.com/news/technology/argenx-stock-argenx-earnings-q1-2025/"
X Link 2025-05-08T15:52Z [---] followers, [---] engagements
"$ADMA plummeted after its first-quarter sales and profit missed expectations. But the company raised its sales outlook for [----] and [----]. https://www.investors.com/news/technology/adma-stock-adma-biologics-earnings-q1-2025/ https://www.investors.com/news/technology/adma-stock-adma-biologics-earnings-q1-2025/"
X Link 2025-05-08T18:07Z [---] followers, [---] engagements
"$PODD broke out and rocketed above the 5% buy zone on its strong earnings report. The company is beginning to make gains in the T2D market. https://www.investors.com/news/technology/insulet-stock-insulet-earnings-q1-2025/ https://www.investors.com/news/technology/insulet-stock-insulet-earnings-q1-2025/"
X Link 2025-05-09T17:01Z [---] followers, [---] engagements
"ICYMI: $EXEL rocketed to a record high after obliterating first-quarter expectations and raising its full-year guidance by $100 million. https://www.investors.com/news/technology/exelixis-stock-exelixis-earnings-q1-2025/ https://www.investors.com/news/technology/exelixis-stock-exelixis-earnings-q1-2025/"
X Link 2025-05-14T16:47Z [---] followers, [---] engagements
"$NVO inked another obesity deal Wednesday sending $SEPN shares flying. They will focus on developing four GPCR-targeting drugs in combination with the usual suspects in weight loss: GLP-1 GIP and glucagon receptors. https://www.investors.com/news/technology/novo-nordisk-obesity-deal-septerna-gpcr/ https://www.investors.com/news/technology/novo-nordisk-obesity-deal-septerna-gpcr/"
X Link 2025-05-14T16:49Z [---] followers, [---] engagements
"$ISRG CEO Gary Guthart announced his plan to step down and assume the board chair role. He will be succeeded by Dave Rosa who has been with Intuitive Surgical for nearly three decades. https://www.investors.com/news/technology/intuitive-surgical-stock-ceo-transition-gary-guthart-dave-rosa/ https://www.investors.com/news/technology/intuitive-surgical-stock-ceo-transition-gary-guthart-dave-rosa/"
X Link 2025-05-15T17:51Z [---] followers, [---] engagements
"$BMRN is buying $INZY for $270 million. The deal bolsters BioMarin's enzyme replacement therapy business. https://www.investors.com/news/technology/biomarin-inozyme-acquisition-enzyme-replacement-therapy-ert/ https://www.investors.com/news/technology/biomarin-inozyme-acquisition-enzyme-replacement-therapy-ert/"
X Link 2025-05-16T16:58Z [---] followers, [---] engagements
"The biggest pharma news of the day though is probably the ousting of $NVO's CEO amid a steep stock decline and increasing competition for its weight-loss drug. $LLY $AMGN $VKTX $AZN $RHHBY https://www.investors.com/news/technology/novo-nordisk-stock-ceo-transition-eli-lilly-weight-loss-drugs/ https://www.investors.com/news/technology/novo-nordisk-stock-ceo-transition-eli-lilly-weight-loss-drugs/"
X Link 2025-05-16T16:59Z [---] followers, [---] engagements
"$MRNA reversed its recent rally after the company pulled its application for a combo Covid/flu shot. The news come a day after the FDA put out a new framework for how it will approve Covid shots going forward. https://www.investors.com/news/technology/moderna-stock-covid-flu-combination-shot/ https://www.investors.com/news/technology/moderna-stock-covid-flu-combination-shot/"
X Link 2025-05-21T16:23Z [---] followers, [--] engagements
"Here's how the FDA will analyze the effectiveness of Covid vaccines in the future: $PFE $MRNA $BNTX $NVAX https://www.investors.com/news/technology/moderna-vaccine-stocks-fda-covid-vaccine-approvals/ https://www.investors.com/news/technology/moderna-vaccine-stocks-fda-covid-vaccine-approvals/"
X Link 2025-05-21T16:24Z [---] followers, [--] engagements
"$MDT announced plans to spin off its nearly $3 billion a year diabetes business. Once the spinoff completes potentially via an IPO the new company will be the only to have CGMs and insulin pumps. $ABT $DXCM $TNDM $PODD https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q4-2025/ https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q4-2025/"
X Link 2025-05-21T16:30Z [---] followers, [---] engagements
"$NVO is losing steam to $LLY in the battle for weight-loss leadership. But Novo is inking deals left and right (including with $HIMS) Wegovy won $CVS' Caremark position and Novo could be first with an obesity pill. Can it reverse its fortunes"
X Link 2025-05-29T16:12Z [---] followers, [---] engagements
"$REGN and $SNY slumped after their experimental COPD drug showed mixed results -- topping the bar for effectiveness in one study and showing "almost no benefit" in a second an RBC analyst said. https://www.investors.com/news/technology/regeneron-stock-sanofi-stock-copd-treatment-failure/ https://www.investors.com/news/technology/regeneron-stock-sanofi-stock-copd-treatment-failure/"
X Link 2025-05-30T16:56Z [---] followers, [---] engagements
"$SMMT crashed after its anti-PD-1/VEGF bispecific missed the bar for overall survival in a highly watched study. The results could bode well for $MRK's Keytruda a top-selling PD-1 used in combination with chemo for numerous cancer types"
X Link 2025-05-30T16:57Z [---] followers, [---] engagements
"$MLTX catapulted on a rumored $3 billion takeover offer from $MRK. One analyst says $5 billion makes more sense and another says I&T deals tend to nab 70%-plus premiums. https://www.investors.com/news/technology/biotech-stock-moonlake-immunotherapeutics-takeover-merck/ https://www.investors.com/news/technology/biotech-stock-moonlake-immunotherapeutics-takeover-merck/"
X Link 2025-06-03T15:55Z [---] followers, [---] engagements
"ICYMI: I wrote yesterday about $AZN's efforts in cancer treatment. The company unveiled promising results at #ASCO2025 for drugs that could treat forms of breast and gastric cancer. https://www.investors.com/news/technology/astrazeneca-azn-breast-cancer-treatment-asco/ https://www.investors.com/news/technology/astrazeneca-azn-breast-cancer-treatment-asco/"
X Link 2025-06-03T15:58Z [---] followers, [--] engagements
"There's a new twist in $REGN's bid to buy 23andMe. https://www.investors.com/news/technology/23andme-former-ceo-anne-wojcicki-regeneron-pharmaceuticals/ https://www.investors.com/news/technology/23andme-former-ceo-anne-wojcicki-regeneron-pharmaceuticals/"
X Link 2025-06-05T18:01Z [---] followers, [---] engagements
"$ADA25 is coming. Here's what investors are looking for from $AMGN's MariTide. $LLY $NVO https://www.investors.com/news/technology/amgen-maritide-weight-loss-drug-ada-2025/ https://www.investors.com/news/technology/amgen-maritide-weight-loss-drug-ada-2025/"
X Link 2025-06-06T17:59Z [---] followers, [---] engagements
"$MTSR stock jumped -- as high as 28% -- after the company reported promising results for its amylin-focused obesity treatment. $LLY $NVO $ABBV https://www.investors.com/news/technology/metsera-weight-loss-drug-amylin/ https://www.investors.com/news/technology/metsera-weight-loss-drug-amylin/"
X Link 2025-06-09T17:10Z [---] followers, [---] engagements
"$MRNA is under pressure after HHS fired all [--] members of the CDC's ACIP. $PFE reversed higher while other stocks were mixed. https://www.investors.com/news/technology/vaccine-stocks-rfk-jr-cdc-acip/ https://www.investors.com/news/technology/vaccine-stocks-rfk-jr-cdc-acip/"
X Link 2025-06-10T15:00Z [---] followers, [---] engagements
"$SRPT plummeted after a second patient died following treatment with DMD gene therapy Elevidys. The boy was [--] years old and non-ambulatory but analysts say this could affect uptake among ambulatory patients as well. https://www.investors.com/news/technology/sarepta-stock-plummets-gene-therapy-recipient-dies/ https://www.investors.com/news/technology/sarepta-stock-plummets-gene-therapy-recipient-dies/"
X Link 2025-06-16T17:25Z [---] followers, [---] engagements
"The New America this week takes a look at $HIMS which is making waves in the weight-loss space after signing a deal to bundle a Hims & Hers membership with $NVO's Wegovy. https://www.investors.com/news/technology/hims-stock-hims-health-obesity-drugs/ https://www.investors.com/news/technology/hims-stock-hims-health-obesity-drugs/"
X Link 2025-06-20T15:59Z [---] followers, [---] engagements
"$NVO and $HIMS took their feud public Monday after Novo Nordisk scrapped its deal with Hims & Hers over concerns about compounded semaglutide. Hims though says Novo was pressuring its sales team to push patients to Wegovy over other options"
X Link 2025-06-23T20:36Z [---] followers, [---] engagements
"Read on for the latest: https://www.investors.com/news/technology/hims-stock-novo-nordisk-ends-deal-wegovy-knockoffs-compounded-semaglutide/ https://www.investors.com/news/technology/hims-stock-novo-nordisk-ends-deal-wegovy-knockoffs-compounded-semaglutide/"
X Link 2025-06-23T20:36Z [---] followers, [--] engagements
"$EXEL surged on promising results for its next-generation drug in patients with metastatic colon cancer. https://www.investors.com/news/technology/exelixis-stock-next-generation-cancer-drug-colon-cancer/ https://www.investors.com/news/technology/exelixis-stock-next-generation-cancer-drug-colon-cancer/"
X Link 2025-06-23T20:37Z [---] followers, [---] engagements
"$BIIB stock is flat but reported promising results for its next-generation SMA drug. If approved it could be a once-yearly treatment vs. the four loading doses and maintenance doses every four months for Spinraza. https://www.investors.com/news/technology/biogen-next-generation-spinraza-spinal-muscular-atrophy-treatment/ https://www.investors.com/news/technology/biogen-next-generation-spinraza-spinal-muscular-atrophy-treatment/"
X Link 2025-06-25T16:26Z [---] followers, [---] engagements
"The FDA said Wednesday it's investigating the two patient deaths following treatment with $SRPT's Elevidys. Sarepta stock dropped again. https://www.investors.com/news/technology/sarepta-stock-elevidys-deaths-fda-investigation/ https://www.investors.com/news/technology/sarepta-stock-elevidys-deaths-fda-investigation/"
X Link 2025-06-25T17:50Z [---] followers, [---] engagements
"$VKTX is enrolling its Phase [--] studies for obesity candidate VK2735. Two analysts are impressed with the company's strategy. https://www.investors.com/news/technology/viking-therapeutics-stock-weight-loss-drugs-phase-3-testing/ https://www.investors.com/news/technology/viking-therapeutics-stock-weight-loss-drugs-phase-3-testing/"
X Link 2025-06-25T19:17Z [---] followers, [---] engagements
"$GILD and $EXAS rose after the Supreme Court shot down a challenge to a key ACA provision. https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeztugo-supreme-court-decision/ https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeztugo-supreme-court-decision/"
X Link 2025-06-27T19:15Z [---] followers, [---] engagements
"$MRNA rose moderately after the company unveiled late-stage results for its flu shot. The results could be telling for the company's Covid/flu combination. https://www.investors.com/news/technology/moderna-stock-flu-shot-phase-3/ https://www.investors.com/news/technology/moderna-stock-flu-shot-phase-3/"
X Link 2025-06-30T17:52Z [---] followers, [---] engagements
"$PTGX just announced it will move a triple agonist -- targeting GLP-1 GIPR and the glucagon receptor -- into clinical testing. This is similar to $LLY's retatrutide. https://www.investors.com/news/technology/protagonist-therapeutics-obesity-treatment-eli-lilly-retatrutide/ https://www.investors.com/news/technology/protagonist-therapeutics-obesity-treatment-eli-lilly-retatrutide/"
X Link 2025-06-30T20:10Z [---] followers, [---] engagements
"$MRK announces $10 billion takeover of $VRNA which makes Ohtuvayre a treatment for COPD. https://www.investors.com/news/technology/verona-pharma-merck-takeover/ https://www.investors.com/news/technology/verona-pharma-merck-takeover/"
X Link 2025-07-09T17:55Z [---] followers, [---] engagements
"$RYTM surged to a record high on promising test results for a drug that would treat a form obesity. https://www.investors.com/news/technology/rhythm-pharmaceuticals-stock-record-high-obesity-results/ https://www.investors.com/news/technology/rhythm-pharmaceuticals-stock-record-high-obesity-results/"
X Link 2025-07-09T17:56Z [---] followers, [---] engagements
"$JNJ easily beat second-quarter expectations and raised its outlook for the year. But the Dow Jones health giant's report is also promising for $SYK $MDT and $BSX. Here's why: https://www.investors.com/news/technology/johnson-johnson-stock-j-j-earnings-q2-205/ https://www.investors.com/news/technology/johnson-johnson-stock-j-j-earnings-q2-205/"
X Link 2025-07-16T16:41Z [---] followers, [---] engagements
"My I&T feature this week takes a look at $INSM which is on the cusp of an FDA decision for its brensocatib a potential treatment for a chronic lung disease. But that's just the tip of the iceberg says CEO Will Lewis. https://www.investors.com/news/technology/insmed-stock-tpip-brensocatib-arikayce/ https://www.investors.com/news/technology/insmed-stock-tpip-brensocatib-arikayce/"
X Link 2025-07-24T16:52Z [---] followers, [----] engagements
"In earnings news $ZTS $HIMS and $VRTX all took their hits on Tuesday. Zoetis was rattled by its arthritis drug Librela while investors are now questioning Hims' growth expectations. Vertex meanwhile faced two pain drug setbacks"
X Link 2025-08-05T20:46Z [---] followers, [---] engagements
"Read on: Zoetis: Hims: Vertex: https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q2-2025/ https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q2-2025/ https://www.investors.com/news/technology/zoetis-stock-zoetis-earnings-q2-205/ https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q2-2025/ https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q2-2025/ https://www.investors.com/news/technology/zoetis-stock-zoetis-earnings-q2-205/"
X Link 2025-08-05T20:47Z [---] followers, [---] engagements
"$LLY crumbled after its obesity pill orforglipron missed expectations in a 72-week study. The results hammered Eli Lilly shares and sent $VKTX and $NVO higher. $GPCR has reversed lower more recently however. https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q2-2025/ https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q2-2025/"
X Link 2025-08-07T17:05Z [---] followers, [---] engagements
"$EXAS is under pressure after signing a licensing deal for Freenome's blood-based CRC test. Analysts debate the merits of the deal. https://www.investors.com/news/technology/exact-sciences-stock-exact-sciences-earnings-q2-2025-freenome-blood-test/ https://www.investors.com/news/technology/exact-sciences-stock-exact-sciences-earnings-q2-2025-freenome-blood-test/"
X Link 2025-08-07T17:05Z [---] followers, [---] engagements
"$PODD beat second-quarter expectations and raised its outlook yet again. The company is still in the early innings of winning business in the type [--] diabetes space. https://www.investors.com/news/technology/insulet-stock-insulet-earnings-q2-2025/ https://www.investors.com/news/technology/insulet-stock-insulet-earnings-q2-2025/"
X Link 2025-08-07T17:06Z [---] followers, [---] engagements
"2/2 I should have done more work at the outset. The story has now been updated with additional context. $LQDA https://www.investors.com/news/technology/liquidia-stock-liquidia-earnings-q2-2025/ https://www.investors.com/news/technology/liquidia-stock-liquidia-earnings-q2-2025/"
X Link 2025-08-12T19:39Z [---] followers, [----] engagements
"$ARWR pulled back after $SRPT liquified its stake in the biotech company. One analyst says the deal is a win-win allowing Sarepta to bolster its cash runway while also allowing Arrowhead to repurchase its shares in a non-dilutive way. https://www.investors.com/news/technology/sarepta-therapeutics-arrowhead-pharmaceuticals-stake/ https://www.investors.com/news/technology/sarepta-therapeutics-arrowhead-pharmaceuticals-stake/"
X Link 2025-08-14T16:05Z [---] followers, [---] engagements
"$LLY is hiking its list price on Mounjaro in the UK in response to Trump's Most Favored Nation executive order. https://www.investors.com/news/technology/eli-lilly-uk-list-price-mounjaro-most-favored-nation-drug-prices/ https://www.investors.com/news/technology/eli-lilly-uk-list-price-mounjaro-most-favored-nation-drug-prices/"
X Link 2025-08-14T17:23Z [---] followers, [---] engagements
"$MDT has a new activist investor. Here's how the new investor is shaking things up. https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q1-2026/ https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q1-2026/"
X Link 2025-08-19T20:07Z [---] followers, [---] engagements
"IBD #SOTD $PODD broke out following its strong second-quarter report earlier this month. Momentum is continuing in the type [--] diabetes space. https://www.investors.com/research/ibd-stock-of-the-day/insulet-stock-breaks-out-omnipod-sales/ https://www.investors.com/research/ibd-stock-of-the-day/insulet-stock-breaks-out-omnipod-sales/"
X Link 2025-08-19T20:08Z [---] followers, [---] engagements
"IBD #SOTD $BSX is flashing several early buy signals after its "dynamic duo" helped drive a second-quarter beat-and-raise. https://www.investors.com/research/ibd-stock-of-the-day/boston-scientific-stock-breaks-out/ https://www.investors.com/research/ibd-stock-of-the-day/boston-scientific-stock-breaks-out/"
X Link 2025-08-20T20:03Z [---] followers, [---] engagements
"$GILD dipped after $CVS said it wouldn't add Yeztugo the twice-a-year shot to its drug coverage list for now. Yeztugo goes for $28000 a year before insurance making it more expensive than other PrEP drugs. https://www.investors.com/news/technology/gilead-stock-hiv-prevention-yeztugo-cvs-health/ https://www.investors.com/news/technology/gilead-stock-hiv-prevention-yeztugo-cvs-health/"
X Link 2025-08-21T17:19Z [---] followers, [---] engagements
"$GILD won approval in Europe for its twice-a-year shot to prevent HIV. The drug just faced a setback in the U.S. however. https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeytuo-yeztugo/ https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeytuo-yeztugo/"
X Link 2025-08-26T15:57Z [---] followers, [---] engagements
"$LLY said Tuesday it will soon ask for approval of its weight-loss pill on the back of promising results in patients with type [--] diabetes. $NVO and $VKTX slipped on the news. https://www.investors.com/news/technology/eli-lilly-weight-loss-pill-viking-therapeutics-novo-nordisk/ https://www.investors.com/news/technology/eli-lilly-weight-loss-pill-viking-therapeutics-novo-nordisk/"
X Link 2025-08-26T15:57Z [---] followers, [---] engagements
"RFK Jr. made good on his promise to end Covid vaccine mandates. $BNTX fell while $PFE $MRNA and $NVAX climbed in response. https://www.investors.com/news/technology/biontech-stock-fda-approval-covid-vaccine-rfk-vaccine-mandates/ https://www.investors.com/news/technology/biontech-stock-fda-approval-covid-vaccine-rfk-vaccine-mandates/"
X Link 2025-08-27T21:16Z [---] followers, [---] engagements
"RFK Jr. is on thin ice with the Senate following a grilling Thursday over vaccine policies in the U.S. $MRNA $PFE $BNTX $NVAX https://www.investors.com/news/technology/covid-vaccines-donald-trump-pfizer-moderna/ https://www.investors.com/news/technology/covid-vaccines-donald-trump-pfizer-moderna/"
X Link 2025-09-05T17:05Z [---] followers, [---] engagements
"When $HIMS knocked off Wegovy it didn't just anger $NVO. It lit a fire beneath the beleaguered telehealth industry which was still limping away from the Covid pandemic. My A1 for the week: https://www.investors.com/news/technology/telehealth-industry-hims-stock/ https://www.investors.com/news/technology/telehealth-industry-hims-stock/"
X Link 2025-09-19T13:08Z [---] followers, [----] engagements
"ACIP voted to end the universal Covid vaccine recommendation but were split on whether to require prescriptions. Ultimately the latter failed. $PFE $MRNA $BNTX $NVAX"
X Link 2025-09-19T19:26Z [---] followers, [---] engagements
"ICYMI: On Friday the FDA approved subcutaneous Keytruda. It will take just two minutes to administer vs. [--] minutes for the IV formulation. $MRK https://www.investors.com/news/technology/merck-subcutaneous-keytruda-approved/ https://www.investors.com/news/technology/merck-subcutaneous-keytruda-approved/"
X Link 2025-09-22T17:10Z [---] followers, [---] engagements
"$TEM initially flew higher but shares have settled to a sub-2% gain after the FDA cleared the company's new RNA-based assay for investigating cancer. https://www.investors.com/news/technology/tempus-ai-stock-record-high-rna-sequencing-device/ https://www.investors.com/news/technology/tempus-ai-stock-record-high-rna-sequencing-device/"
X Link 2025-09-22T17:11Z [---] followers, [---] engagements
"The FDA declined to approve $SRRK's SMA drug citing issues at the Catalent fill-finish facility in Indiana. But the stock has come back from steep premarket gains with analysts noting this is likely a few months' delay. https://www.investors.com/news/technology/scholar-rock-stock-catalent-sma-drug/ https://www.investors.com/news/technology/scholar-rock-stock-catalent-sma-drug/"
X Link 2025-09-23T15:27Z [---] followers, [---] engagements
"President Donald Trump's plan to lower U.S. drug prices is facing its first big test: compliance. Here's what we know as rumors fly that the White House will soon make a drug-pricing announcement. https://www.investors.com/news/technology/most-favored-nation-drug-prices/ https://www.investors.com/news/technology/most-favored-nation-drug-prices/"
X Link 2025-09-30T14:32Z [---] followers, [---] engagements
"ICYMI: Here's what we know about TrumpRx how it will affect drugmakers and whether it will benefit patients. $PFE $LLY $BMY $ABBV https://www.investors.com/news/technology/most-favored-nation-drug-prices/ https://www.investors.com/news/technology/most-favored-nation-drug-prices/"
X Link 2025-10-01T18:47Z [---] followers, [---] engagements
"$AMGN is the latest to join in launching AmgenNow to make cholesterol drug Repatha available at a lower price. It will cost $239 a month which is roughly a 60% discount to its list price. https://www.investors.com/news/technology/most-favored-nation-drug-prices/ https://www.investors.com/news/technology/most-favored-nation-drug-prices/"
X Link 2025-10-06T15:29Z [---] followers, [---] engagements
"Earnings season kicked off for pharmaceuticals today with bellwether $JNJ. Sales and EPS beat forecasts but shares fell on a surprise spinoff. https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q3-2025/ https://www.investors.com/news/technology/johnson-johnson-stock-johnson-johnson-earnings-q3-2025/"
X Link 2025-10-14T15:54Z [---] followers, [---] engagements
"This week's New America takes a look at $ARQT an IBD [--] stock focused on its "pipeline in a product" a skin disease treatment that takes on various concentrations and two formulations. https://www.investors.com/research/the-new-america/arcutis-biotherapeutics-arcutis-stock-zoryve/ https://www.investors.com/research/the-new-america/arcutis-biotherapeutics-arcutis-stock-zoryve/"
X Link 2025-03-28T16:29Z [---] followers, [---] engagements
"$AZN said its experimental PCSK9 blocker lowered LDL cholesterol by nearly 51% when added to statins. That outperformed rival pills from $MRK and $NAMS but AstraZeneca stock fell in line with broader pharma stocks. https://www.investors.com/news/technology/astrazeneca-stock-cholesterol-treatment-pcsk9-oral/ https://www.investors.com/news/technology/astrazeneca-stock-cholesterol-treatment-pcsk9-oral/"
X Link 2025-03-31T16:24Z [---] followers, [---] engagements
"$NVS won FDA approval for its IgA nephropathy drug Vanrafia. It comes without a black box warnings or a REMS. But analysts say $TVTX's Filspari which does have those measures isn't struggling to gain traction. https://www.investors.com/news/technology/novartis-stock-iga-nephropathy-approval-travere-therapeutics/ https://www.investors.com/news/technology/novartis-stock-iga-nephropathy-approval-travere-therapeutics/"
X Link 2025-04-03T20:35Z [---] followers, [---] engagements
"$DXCM surged after the FDA cleared its new G7 [--] Day CGM. The company touts the longest wear time at [----] days (which includes a 12-hour grace period to swap out devices). $ABT $MDT https://www.investors.com/news/technology/dexcom-stock-fda-clearance-g7-15-days/ https://www.investors.com/news/technology/dexcom-stock-fda-clearance-g7-15-days/"
X Link 2025-04-10T15:15Z [---] followers, [---] engagements
"It's been a busy earnings morning on the biopharma side. $AZN and $PFE reported mixed earnings -- both beat profits views but missed sales estimates. $NVS scored a beat-and-raise but $REGN took a hit on light Eylea sales"
X Link 2025-04-29T17:23Z [---] followers, [---] engagements
"Novartis: AstraZeneca: Pfizer: Regeneron: https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q1-2025/ https://www.investors.com/news/technology/pfizer-stock-pfizer-earnings-q1-2025/ https://www.investors.com/news/technology/astrazeneca-stock-astrazeneca-earnings-q1-2025/ https://www.investors.com/news/technology/novartis-stock-novartis-earnings-q1-2025/ https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q1-2025/ https://www.investors.com/news/technology/pfizer-stock-pfizer-earnings-q1-2025/"
X Link 2025-04-29T17:23Z [---] followers, [---] engagements
"The CMS draft guidance had some potential bad news for $HALO. Shares plunged by double digits in early Tuesday trades. https://www.investors.com/news/technology/halozyme-therapeutics-medicare-inflation-reduction-act-hyaluronidase-enhanze/ https://www.investors.com/news/technology/halozyme-therapeutics-medicare-inflation-reduction-act-hyaluronidase-enhanze/"
X Link 2025-05-13T15:43Z [---] followers, [---] engagements
"The wonderful @IBD_Alexis put together a fantastic video explainer on the MRD market focusing on the efforts by $EXAS $GH and $NTRA. It follows a story I wrote for A1 earlier this year about the massive market for liquid biopsies. https://www.investors.com/ibd-videos/videos/inside-the-multibillion-dollar-cancer-detection-market https://www.investors.com/ibd-videos/videos/inside-the-multibillion-dollar-cancer-detection-market"
X Link 2025-05-14T22:07Z [---] followers, [---] engagements
"IBD [--] stock $TVTX nosedived after the FDA decided to hold an advisory committee meeting for its drug Filspari ahead of a potential approval in FSGS treatment. It's not the only stock to face that setback this week. https://www.investors.com/news/technology/travere-therapeutics-filspari-fsgs-advisory-committee-meeting/ https://www.investors.com/news/technology/travere-therapeutics-filspari-fsgs-advisory-committee-meeting/"
X Link 2025-05-16T16:58Z [---] followers, [---] engagements
"$REGN won the right to buy 23andMe $MEHCQ for $256 million at the bankruptcy auction. The biotech giant says it will maintain 23andMe's consumer genome services. https://www.investors.com/news/technology/23andme-biotech-buyer-regeneron-pharmaceuticals/ https://www.investors.com/news/technology/23andme-biotech-buyer-regeneron-pharmaceuticals/"
X Link 2025-05-19T15:21Z [---] followers, [---] engagements
"$BSX said Wednesday it would stop selling its TAVR system after a failed clinical study muddied the path forward for approval. $EW and $MDT jumped. $ABT which was originally in the green is now down slightly. https://www.investors.com/news/technology/edwards-lifesciences-stock-boston-scientific-tavr/ https://www.investors.com/news/technology/edwards-lifesciences-stock-boston-scientific-tavr/"
X Link 2025-05-28T15:25Z [---] followers, [---] engagements
"$VEEV surged after the company reported strong fiscal first-quarter earnings. Shares broke out of a consolidation and the RS line hit a new high. https://www.investors.com/news/technology/veeva-stock-veeva-systems-earnings-q1-2026-2/ https://www.investors.com/news/technology/veeva-stock-veeva-systems-earnings-q1-2026-2/"
X Link 2025-05-29T15:35Z [---] followers, [--] engagements
"$INSM catapulted and broke out after presenting positive results for its rival to PAH drugs from $UTHR and $LQDA. https://www.investors.com/news/technology/insmed-stock-pah-treatment-united-therapeutics-liquidia/ https://www.investors.com/news/technology/insmed-stock-pah-treatment-united-therapeutics-liquidia/"
X Link 2025-06-10T15:02Z [---] followers, [---] engagements
"$SUPN is buying $SAGE after numerous setbacks hammered the biotech stock over the last few years. $BIIB tried to buy it earlier this year but Supernus put together a bigger offer. https://www.investors.com/news/technology/sage-therapeutics-takeover-supernus-pharmaceuticals/ https://www.investors.com/news/technology/sage-therapeutics-takeover-supernus-pharmaceuticals/"
X Link 2025-06-16T17:26Z [---] followers, [---] engagements
"$CRMD inked an expanded deal for its DefenCath with a large dialysis organization and raised its sales outlook for the second quarter. $DVA https://www.investors.com/news/technology/cormedix-stock-defencath-large-dialysis-organization/ https://www.investors.com/news/technology/cormedix-stock-defencath-large-dialysis-organization/"
X Link 2025-06-23T20:39Z [---] followers, [---] engagements
"$KVUE which is known for brands like Aveeno Band-Aid Listerine and Tylenol yo-yoed after the CEO stepped down amid a strategic review. Kenvue is facing off with Starboard Value an activist investor. https://www.investors.com/news/technology/kenvue-stock-ceo-change-strategic-review/ https://www.investors.com/news/technology/kenvue-stock-ceo-change-strategic-review/"
X Link 2025-07-14T17:16Z [---] followers, [---] engagements
"ICYMI: $EW is benefitting after $BSX exited the TAVR market. Boston Scientific though continues to rise on excitement for its cardiovascular portfolio. https://www.investors.com/news/technology/edwards-lifesciences-stock-edwards-lifesciences-earnings-q2-2025/ https://www.investors.com/news/technology/edwards-lifesciences-stock-edwards-lifesciences-earnings-q2-2025/"
X Link 2025-07-25T20:34Z [---] followers, [---] engagements
"$TGTX is a top 3% biotech stock. But shares crumbled after the company's second-quarter report. Here's why. https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q2-2025/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q2-2025/"
X Link 2025-08-04T15:39Z [---] followers, [---] engagements
"$AXGN plunged after the FDA delayed the review date for its nerve graft product. But one analyst isn't sweating it. https://www.investors.com/news/technology/axogen-stock-fda-delay-avance-nerve-graft/ https://www.investors.com/news/technology/axogen-stock-fda-delay-avance-nerve-graft/"
X Link 2025-08-25T17:23Z [---] followers, [---] engagements
"$DNTH surged Monday on promising results for its generalized myasthenia gravis treatment a potential rival to drugs from $ARGX $AZN and $SNY. Shares ran up markedly ahead of the readout. https://www.investors.com/news/technology/dianthus-therapeutics-stock-argenx-vyvgart/ https://www.investors.com/news/technology/dianthus-therapeutics-stock-argenx-vyvgart/"
X Link 2025-09-08T20:14Z [---] followers, [---] engagements
"$CRNX surged after the company won FDA approval for the first new acromegaly drug in decades. Acromegaly is a form of gigantism famously suffered by Andre Rene Roussimoff widely known as "Andre the Giant." https://www.investors.com/news/technology/crinetics-pharmaceuticals-approves-palsonify-acromegaly-treatment/ https://www.investors.com/news/technology/crinetics-pharmaceuticals-approves-palsonify-acromegaly-treatment/"
X Link 2025-09-26T17:47Z [---] followers, [---] engagements
"More on the earnings front $ABT came up mixed with sales narrowly missing expectations. One analyst noted FX could have had a role to play there. https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-earnings-q3-2025/ https://www.investors.com/news/technology/abbott-stock-abbott-laboratories-earnings-q3-2025/"
X Link 2025-10-15T17:12Z [---] followers, [---] engagements
"$OMER is up triple digits after $NVO agreed to a licensing deal for its potential treatment for rare blood and kidney diseases. https://www.investors.com/news/technology/omeros-stock-novo-nordisk-licensing-deal/ https://www.investors.com/news/technology/omeros-stock-novo-nordisk-licensing-deal/"
X Link 2025-10-15T17:13Z [---] followers, [---] engagements
"$HOLX agreed to an $18.3 billion take-private deal. Shares rose last week on rumors Blackstone and TPG bid $16 billion to buy it. https://www.investors.com/news/technology/hologic-blackstone-tpg-take-private-acquisition/ https://www.investors.com/news/technology/hologic-blackstone-tpg-take-private-acquisition/"
X Link 2025-10-21T17:20Z [---] followers, [---] engagements
"$DHR surged topping its buy zone on a strong earnings report backed by its bioprocessing division. https://www.investors.com/news/technology/danaher-stock-danaher-earnings-q3-2025/ https://www.investors.com/news/technology/danaher-stock-danaher-earnings-q3-2025/"
X Link 2025-10-21T17:20Z [---] followers, [---] engagements
"ICYMI: $ISRG smashed earnings expectations late Tuesday. Shares are up by double digits today helped by the hiked procedure growth guidance for [----]. https://www.investors.com/news/technology/intuitive-surgical-stock-intuitive-surgical-earnings-q3-2025/ https://www.investors.com/news/technology/intuitive-surgical-stock-intuitive-surgical-earnings-q3-2025/"
X Link 2025-10-22T19:28Z [---] followers, [---] engagements
"$BSX jumped after one of its key segments posted 63% sales growth. https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q3-2025/ https://www.investors.com/news/technology/boston-scientific-stock-boston-scientific-earnings-q3-2025/"
X Link 2025-10-22T19:33Z [---] followers, [---] engagements
"Here's what confused the Street about $ALKS' buyout of $AVDL says one analyst. https://www.investors.com/news/technology/avadel-pharmaceuticals-alkermes-buyout-sleep-disorders/ https://www.investors.com/news/technology/avadel-pharmaceuticals-alkermes-buyout-sleep-disorders/"
X Link 2025-10-22T19:33Z [---] followers, [---] engagements
"On the earnings front $MEDP had a strong showing with a massive 1.20x book-to-bill ratio that impressed investors and analysts. The company beat its own forecast for 1.15x. https://www.investors.com/news/technology/medpace-stock-medpace-holdings-earnings-q3-2025/ https://www.investors.com/news/technology/medpace-stock-medpace-holdings-earnings-q3-2025/"
X Link 2025-10-23T20:26Z [---] followers, [---] engagements
"$VKTX stock also put up a strong showing after the company said it expects to finish enrolling patients in two Phase [--] obesity treatment studies later this year and early next. https://www.investors.com/news/technology/viking-therapeutics-stock-obesity-treatment-studies/ https://www.investors.com/news/technology/viking-therapeutics-stock-obesity-treatment-studies/"
X Link 2025-10-23T20:27Z [---] followers, [---] engagements
"$MTSR says $PFE's claims are "nonsense." The latter is suing Metsera and $NVO over their proposed $6.5 billion deal. Novo swooped in last week widely Pfizer's $4.9 billion deal to buy Metsera an obesity-focused biotech. https://www.investors.com/news/technology/metsera-pfizer-novo-nordisk-takeover-litigation/ https://www.investors.com/news/technology/metsera-pfizer-novo-nordisk-takeover-litigation/"
X Link 2025-11-03T18:19Z [---] followers, [---] engagements
"$QURE is under pressure down roughly 50% after the FDA issued unexpected feedback on its gene therapy for Huntington's disease. The news comes less than six weeks after UniQure stock skyrocketed almost 250% on positive test results. https://www.investors.com/news/technology/uniqure-stock-huntingtons-gene-therapy-fda-feedback/ https://www.investors.com/news/technology/uniqure-stock-huntingtons-gene-therapy-fda-feedback/"
X Link 2025-11-03T18:21Z [---] followers, [---] engagements
"I got [--] minutes this morning to chat with $NVO's CFO Karsten Munk Knudsen about $MTSR $HIMS $LLY and of course the company's third guidance cut this year. Here's why he says Novo Nordisk's "hyper growth" has stalled. https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q3-2025/ https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q3-2025/"
X Link 2025-11-05T21:25Z [---] followers, [---] engagements
"It's been a wild week for the weight-loss drugs segment with $LLY and $NVO inking MFN deals and Novo duking it out with $PFE to buy $MTSR. Earlier this year obesity stocks were in a rut. Now Some of them are telling a different story. https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/ https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/"
X Link 2025-11-07T22:55Z [---] followers, [---] engagements
"ICYMI: $MRK and $CRSP unveiled positive results for cholesterol treatments. Merck's is a daily pill while Crispr's would be a one-time gene-editing treatment. https://www.investors.com/news/technology/crispr-stock-intellia-stock-gene-editing-cholesterol-triglycerides-hae/ https://www.investors.com/news/technology/merck-amgen-regeneron-pcsk9-pill-cholesterol-treatment/ https://www.investors.com/news/technology/crispr-stock-intellia-stock-gene-editing-cholesterol-triglycerides-hae/ https://www.investors.com/news/technology/merck-amgen-regeneron-pcsk9-pill-cholesterol-treatment/"
X Link 2025-11-10T18:34Z [---] followers, [---] engagements
"$ANAB reversed a recent 70% run after its ulcerative colitis drug failed in midstage testing. One analyst pegged it as having only a 15% chance of succeeding. https://www.investors.com/news/technology/anaptysbio-stock-ulcerative-colitis-treatment-failure/ https://www.investors.com/news/technology/anaptysbio-stock-ulcerative-colitis-treatment-failure/"
X Link 2025-11-10T18:35Z [---] followers, [---] engagements
"Meanwhile the battle with $RHHBY and $TGTX continues in multiple sclerosis. TG took the most recent hit. https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-treatment/ https://www.investors.com/news/technology/tg-therapeutics-stock-roche-multiple-sclerosis-treatment/"
X Link 2025-11-10T18:35Z [---] followers, [---] engagements
"Also ICYMI: The $PFE and $NVO battle to acquire $MTSR ended on Friday. Here's how it went down: https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-buyout-battle/ https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-buyout-battle/"
X Link 2025-11-10T18:36Z [---] followers, [---] engagements
"$COGT is up by triple digits on a first in [--] years development in treating second-line GIST. https://www.investors.com/news/technology/cogent-biosciences-stock-gist-treatment/ https://www.investors.com/news/technology/cogent-biosciences-stock-gist-treatment/"
X Link 2025-11-10T19:33Z [---] followers, [---] engagements
"On the M&A and cancer front $JNJ is buying privately held Halda Therapeutics. It's working on oral treatments that could treat a myriad of cancers. https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/ https://www.investors.com/news/technology/johnson-johnson-halda-therapeutics-acquisition/"
X Link 2025-11-17T22:42Z [---] followers, [---] engagements
"$NVO lowered the price of its GLP-1 drugs Ozempic and Wegovy on its NovoCare DTC website. The price is lower than what $LLY charges for its rival drugs Mounjaro and Zepbound. https://www.investors.com/news/technology/novo-nordisk-eli-lilly-trumprx-wegovy-ozempic-price-cuts/ https://www.investors.com/news/technology/novo-nordisk-eli-lilly-trumprx-wegovy-ozempic-price-cuts/"
X Link 2025-11-17T22:42Z [---] followers, [---] engagements
"My I&T feature this week focuses on $LGND the royalty-focused biotech backer behind $TVTX's Filspari and $MRK's Ohtuvayre. https://www.investors.com/news/technology/ligand-pharmaceuticals-royalty-business-biotech/ https://www.investors.com/news/technology/ligand-pharmaceuticals-royalty-business-biotech/"
X Link 2025-11-18T18:23Z [---] followers, [---] engagements
"$MRK said Tuesday sotatercept (branded Winrevair) showed promise in patients with a form of pulmonary hypertension. But the company doesn't seem to be filing with the FDA based on these results. https://www.investors.com/news/technology/merck-stock-pulmonary-hypertension-sotatercept/ https://www.investors.com/news/technology/merck-stock-pulmonary-hypertension-sotatercept/"
X Link 2025-11-18T18:24Z [---] followers, [---] engagements
"$MDT broke out of a flat base helped by massive growth for its pulsed field ablation technology. It rivals $BSX in that segment. https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q3-2025-2/ https://www.investors.com/news/technology/medtronic-stock-medtronic-earnings-q3-2025-2/"
X Link 2025-11-18T18:25Z [---] followers, [---] engagements
"Today's IBD #SOTD takes a look at $MEDP which shot higher on its massive book-to-bill beat in the third quarter. But analysts wonder if Medpace is worth its sky-high valuation relative to other CRO stocks. https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-contract-resource-organization-q3-2025/ https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-contract-resource-organization-q3-2025/"
X Link 2025-11-18T19:32Z [---] followers, [---] engagements
"While quieter than the $NVO and $PFE dustup over Metsera $ALKS and Lundbeck are continuing to trade bids over $AVDL. Today Alkermes has the "superior proposal." https://www.investors.com/news/technology/alkermes-avadel-pharmaceuticals-buyout-lundbeck/ https://www.investors.com/news/technology/alkermes-avadel-pharmaceuticals-buyout-lundbeck/"
X Link 2025-11-19T18:41Z [---] followers, [---] engagements
"$VKTX slumped though the company said it over-enrolled a study of its obesity treatment VK2735. https://www.investors.com/news/technology/viking-therapeutics-stock-enrollment-phase-3-vk2735/ https://www.investors.com/news/technology/viking-therapeutics-stock-enrollment-phase-3-vk2735/"
X Link 2025-11-19T18:42Z [---] followers, [---] engagements
"$AGIO plummeted while $FULC surged after Agios said mitapivat missed its goal in a Phase [--] study of patients with sickle cell disease. https://www.investors.com/news/technology/agios-pharmacuticals-stock-sickle-cell-treatment-mitapivat/ https://www.investors.com/news/technology/agios-pharmacuticals-stock-sickle-cell-treatment-mitapivat/"
X Link 2025-11-19T18:43Z [---] followers, [---] engagements
"My A1 story this week takes a look at the ADC space or what we've been calling "smart bombs" for cancer in the newsroom. It seems all the big oncology names are in this space including $AZN $GSK $ABBV $RHHBY and others. https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/ https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/"
X Link 2025-11-21T16:57Z [---] followers, [---] engagements
"This week's New America feature takes a look at $TVTX which is nearing potential approval of a second condition for its drug Filspari. Filspari treats IgAN but could win the OK to treat another kidney disease FSGS in January. https://www.investors.com/research/the-new-america/travere-therapeutics-stock-kidney-disease-filspari-fsgs/ https://www.investors.com/research/the-new-america/travere-therapeutics-stock-kidney-disease-filspari-fsgs/"
X Link 2025-11-26T17:47Z [---] followers, [---] engagements
"In pharma news CMS revealed the negotiated prices for a basket of [--] drugs beginning in [----]. $NVO and $TEVA shares rose while other stocks were more muted. Unrelated $SNY is under pressure after French authorities raided its Paris HQ. https://www.investors.com/news/technology/novo-nordisk-stock-ozempic-wegovy-ira-discounts/ https://www.investors.com/news/technology/novo-nordisk-stock-ozempic-wegovy-ira-discounts/"
X Link 2025-11-26T17:49Z [---] followers, [---] engagements
"Sanofi confirmed the tax fraud investigation: https://www.investors.com/news/technology/sanofi-stock-paris-raid-tax-fraud-investigation/ https://www.investors.com/news/technology/sanofi-stock-paris-raid-tax-fraud-investigation/"
X Link 2025-11-26T17:49Z [---] followers, [--] engagements
"Our I&T feature is out early this week and takes a look at $BBIO featuring an interview with CEO Neil Kumar. BridgeBio stock has run up by triple digits this year amid several Phase [--] readouts with another in the works. https://www.investors.com/news/technology/bridgebio-pharma-stock-2025/ https://www.investors.com/news/technology/bridgebio-pharma-stock-2025/"
X Link 2025-12-02T17:18Z [---] followers, [---] engagements
"$CAPR surged as much as 535% today -- shares are currently up about 340% -- on promising test results for its cell therapy approach to Duchenne muscular dystrophy. This follows a CRL earlier in the fall. https://www.investors.com/news/technology/capricor-stock-duchenne-muscular-dystrophy/ https://www.investors.com/news/technology/capricor-stock-duchenne-muscular-dystrophy/"
X Link 2025-12-03T19:13Z [---] followers, [---] engagements
"$RCUS tumbled reversing a winning streak over the past eight months after its $GILD-partnered anti-TIGIT drug failed in upper gastrointestinal cancers. https://www.investors.com/news/technology/arcus-biosciences-gilead-sciences-anti-tigit-failure/ https://www.investors.com/news/technology/arcus-biosciences-gilead-sciences-anti-tigit-failure/"
X Link 2025-12-12T18:10Z [---] followers, [---] engagements
"@thehill has a slightly wider camera. I can also see $AMGN and $BMY"
X Link 2025-12-19T19:07Z [---] followers, [--] engagements
"@thehill The full list includes $SNY $NVS $RHHBY's Genentech Boehringer Ingelheim $GILD $BMY $GSK $MRK and $AMGN. Trump says that [--] out of [--] of the biggest pharma companies. He says the other [--] have also signed deals including $JNJ"
X Link 2025-12-19T19:33Z [---] followers, [---] engagements
"$ARWR followed in the footsteps of $WVE silencing the gene responsible for activin E to improve fat loss. Shares are up by double digits. But one analyst says Wave could have the edge. https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/ https://www.investors.com/news/technology/arrowhead-pharmaceuticals-weight-loss-fat-loss-gene-silencing/"
X Link 2026-01-06T16:27Z [---] followers, [----] engagements
"$LLY confirmed its $1.2 billion plan to acquire $VTYX late Wednesday. https://www.investors.com/news/technology/eli-lilly-ventyx-biosciences-ventyx-stock/ https://www.investors.com/news/technology/eli-lilly-ventyx-biosciences-ventyx-stock/"
X Link 2026-01-07T23:16Z [---] followers, [---] engagements
"Here's today's #SOTD which focused on $LLY's rally following the initial rumors of the $VTYX deal. https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-ibd-stock-of-the-day-offers-two-entries-on-rumored-buyout-rally/ https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-ibd-stock-of-the-day-offers-two-entries-on-rumored-buyout-rally/"
X Link 2026-01-07T23:16Z [---] followers, [---] engagements
"#Biotech stocks made a comeback in the latter half of [----] soaring more than 82% from a low point in April amid a flurry of M&A deals and enthusiasm for strong clinical data. Here's what experts are watching for this year. https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/ https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/"
X Link 2026-01-08T16:51Z [---] followers, [---] engagements
"$TVTX was hammered after the company said it just wrapped answering FDA questions ahead of its Jan. [--] PDUFA for Filspari in FSGS. The late FDA request and response could indicate a delay for Filspari. https://www.investors.com/news/technology/travere-therapeutics-stock-fda-review-filspari-fsgs-treatment/ https://www.investors.com/news/technology/travere-therapeutics-stock-fda-review-filspari-fsgs-treatment/"
X Link 2026-01-13T18:50Z [---] followers, [---] engagements
"Today's #SOTD takes a look at $MEDP as shares flirt with an early entry. The biotech funding environment looks strong which could benefits CROs. https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-buy-point-biotech-funding/ https://www.investors.com/research/ibd-stock-of-the-day/medpace-stock-buy-point-biotech-funding/"
X Link 2026-01-13T21:22Z [---] followers, [---] engagements
"$NVO is up 9% at the moment benefitting from a strong first week of Wegovy pill prescriptions. $LLY https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/ https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-prescriptions-eli-lilly-orforglipron/"
X Link 2026-01-16T19:43Z [---] followers, [---] engagements
"$CGON rocketed as much as 44% on promising results for its $JNJ-rivaling bladder cancer drug. https://www.investors.com/news/technology/cg-oncology-johnson-johnson-bladder-cancer-treatment/ https://www.investors.com/news/technology/cg-oncology-johnson-johnson-bladder-cancer-treatment/"
X Link 2025-04-28T15:40Z [---] followers, [---] engagements
"Read more from Neurocrine's report here: Vertex raised the low side of its outlook despite missing Q1 sales calls: Hims is planning to sign more partnerships after the $NVO news last week: https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q1-2025/ https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q1-2025/ https://www.investors.com/news/technology/neurocrine-biosciences-stock-neurocrine-biosciences-earnings-q1-2025/ https://www.investors.com/news/technology/hims-stock-hims-hers-health-earnings-q1-2025/"
X Link 2025-05-06T16:41Z [---] followers, [---] engagements
"$JANX is down almost 50% on mixed results for its prostate cancer treatment. But analysts are upbeat saying its drug could eventually be a blockbuster. https://www.investors.com/news/technology/janux-therapeutics-stock-prostate-cancer-treatment/ https://www.investors.com/news/technology/janux-therapeutics-stock-prostate-cancer-treatment/"
X Link 2025-12-02T17:17Z [---] followers, [---] engagements
"$ALMS more than doubled today on test results for its plaque psoriasis drug a potential rival to oral meds from $JNJ $PTGX and $TAK. https://www.investors.com/news/technology/alumis-biotech-stock-plaque-psoriasis-treatment/ https://www.investors.com/news/technology/alumis-biotech-stock-plaque-psoriasis-treatment/"
X Link 2026-01-06T16:28Z [---] followers, [---] engagements
"$ISRG is under pressure after issuing a lackluster view for [----] procedure growth. $GKOS also took a hit on its guidance. https://www.investors.com/news/technology/intuitive-surgical-stock-robotic-surgery-preannouncement/ https://www.investors.com/news/technology/intuitive-surgical-stock-robotic-surgery-preannouncement/"
X Link 2026-01-14T16:47Z [---] followers, [---] engagements
"$CORT surged after its ovarian cancer regimen met the overall survival bar in a late-stage study. https://www.investors.com/news/technology/corcept-therapeutics-ovarian-cancer-relacorilant/ https://www.investors.com/news/technology/corcept-therapeutics-ovarian-cancer-relacorilant/"
X Link 2026-01-22T17:28Z [---] followers, [---] engagements
"$NVO's oral Wegovy clocked in at [-----] prescriptions (likely not including NovoCare) in its second week. That's far and away north of the [----] from $LLY's Zepbound in its second week of launch. https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-second-week-launch/ https://www.investors.com/news/technology/novo-nordisk-stock-oral-wegovy-second-week-launch/"
X Link 2026-01-23T17:37Z [---] followers, [----] engagements
"An analyst with RBC says $REGN could soon become acquisitive. The press release reads "more direct" on the potential for business development than it has in the past. $SNY $BAYRY https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/ https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/"
X Link 2026-01-30T17:34Z [---] followers, [----] engagements
"$EWTX and $CYTK diverged Wednesday after Edgewise put out promising results for its HCM drug but noted four patients experienced atrial fibrillation. Analysts were mostly unconcerned noting afib tends to occur in the HCM population"
X Link 2025-04-02T16:00Z [---] followers, [---] engagements
"It's important to note Cytokinetics is several years ahead of Edgewise with its PDUFA for aficamten in obstructive HCM scheduled for September. Read on here: https://www.investors.com/news/technology/edgewise-therapeutics-hcm-safety-cytokinetics-aficamten/ https://www.investors.com/news/technology/edgewise-therapeutics-hcm-safety-cytokinetics-aficamten/"
X Link 2025-04-02T16:00Z [---] followers, [---] engagements
"Dollar stock $VIGL skyrocketed after $SNY agreed to buy it for $470 million. The deal includes a CVR that brings the total value up to $600 million. https://www.investors.com/news/technology/sanofi-vigil-neuroscience-acquisition/ https://www.investors.com/news/technology/sanofi-vigil-neuroscience-acquisition/"
X Link 2025-05-22T16:06Z [---] followers, [---] engagements
"$APGE reversed steep premarket gains despite promising results for its eczema drug a potential twice-yearly shot. The results are comparable to $SNY and $REGN's Dupixent and $LLY's Ebglyss. https://www.investors.com/news/technology/apogee-therapeutics-eczema-shot/ https://www.investors.com/news/technology/apogee-therapeutics-eczema-shot/"
X Link 2025-07-07T16:58Z [---] followers, [---] engagements
"Why one analyst says $NVS' $1.4 billion takeover of $TRML just "makes sense." $NVO https://www.investors.com/news/technology/novartis-tourmaline-bio-acquisition/ https://www.investors.com/news/technology/novartis-tourmaline-bio-acquisition/"
X Link 2025-09-09T14:35Z [---] followers, [---] engagements
"$PHVS and $KALV surged after Pharvaris reported promising results for its treatment for HAE attacks. https://www.investors.com/news/technology/pharvaris-kalvista-hae-treatment/ https://www.investors.com/news/technology/pharvaris-kalvista-hae-treatment/"
X Link 2025-12-03T19:15Z [---] followers, [---] engagements
"$ARGX toppled after stopping a study of Vyvgart in patients with thyroid eye disease. Analyst say the decision isn't a big hit for Vyvgart but could bolster $VRDN. https://www.investors.com/news/technology/argenx-stock-vyvgart-thryoid-eye-disease-viridian/ https://www.investors.com/news/technology/argenx-stock-vyvgart-thryoid-eye-disease-viridian/"
X Link 2025-12-15T17:23Z [---] followers, [---] engagements
"#JPM2026 so far has been marked by a slew of preannouncements for the fourth quarter. Here are the winners and losers from day one: $ANY $SRPT $IRTC $DAWN $ANIP https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/ https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/"
X Link 2026-01-12T18:36Z [---] followers, [----] engagements
"$RAPT soared after $GSK agreed to buy it for $2.2 billion. Rapt is working on a preventative treatment for food allergies. https://www.investors.com/news/technology/rapt-stock-gsk-buyout/ https://www.investors.com/news/technology/rapt-stock-gsk-buyout/"
X Link 2026-01-20T18:25Z [---] followers, [---] engagements
"$SRPT surged on promising three-year results for Elevidys. But analysts are split on whether it will help uptake for the embattled gene therapy. $SLDB $RGNX https://www.investors.com/news/technology/sarepta-stock-three-year-elevidys-test-gene-therapy/ https://www.investors.com/news/technology/sarepta-stock-three-year-elevidys-test-gene-therapy/"
X Link 2026-01-26T21:19Z [---] followers, [---] engagements
"$INMD got a boost after an Israeli news site reported the medical aesthetics company is in advanced talks to be acquired for $1.1 billion. https://www.investors.com/news/technology/inmode-stock-takeover-offer-rumor/ https://www.investors.com/news/technology/inmode-stock-takeover-offer-rumor/"
X Link 2026-01-26T21:20Z [---] followers, [---] engagements
"$LLY issued "assertive" guidance Wednesday well above expectations. Analysts say this helps following $NVO's downbeat outlook on Tuesday. https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q4-2025/ https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q4-2025/"
X Link 2026-02-04T17:07Z [---] followers, [---] engagements
"$NVO continued its two-day plunge Wednesday after the company said it expects sales and operating profit to fall this year. Here's what CFO Karsten Knudsen had to say about the outlook and how oral Wegovy could fit in. $LLY https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q4-2025/ https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q4-2025/"
X Link 2026-02-04T17:16Z [---] followers, [---] engagements
"The biotech industry in China is taking off. My A1 feature this week examines why Big Pharma is taking China seriously -- as a partner and a rival. https://www.investors.com/news/technology/biotech-stocks-china-biotech-competition/ https://www.investors.com/news/technology/biotech-stocks-china-biotech-competition/"
X Link 2026-02-06T17:49Z [---] followers, [---] engagements
"@LLCoolJosh22 Thank you Josh I havent examined $IBRX. Dollar stocks are tricky. We tend to focus on higher-value stocks"
X Link 2026-02-07T21:21Z [---] followers, [---] engagements
"$SPRY made a bullish move after reporting its earnings. The company narrowly beat Neffy sales forecasts for [----] though the majority of its revenue came from partnerships and supply agreements. https://www.investors.com/news/technology/ars-pharmaceuticals-stock-earnings-q4-2024/ https://www.investors.com/news/technology/ars-pharmaceuticals-stock-earnings-q4-2024/"
X Link 2025-03-20T16:23Z [---] followers, [--] engagements
"An analyst says $BBIO could change the standard of care in achondroplasia causes disproportionate short-limb stature. The company hit its bull case for the Phase [--] study. https://www.investors.com/news/technology/bridgebio-stock-achondroplasia-treatment/ https://www.investors.com/news/technology/bridgebio-stock-achondroplasia-treatment/"
X Link 2026-02-12T20:36Z [---] followers, [----] engagements
"$HRMY took a hit after the FDA rejected Wakix as a treatment for idiopathic hypersomnia. The drug missed its primary endpoint in Phase [--] testing but the company was hoping the FDA would look at the totality of its data. https://www.investors.com/news/technology/harmony-biosciences-fda-rejects-wakix-idiopathic-hypersomnia/ https://www.investors.com/news/technology/harmony-biosciences-fda-rejects-wakix-idiopathic-hypersomnia/"
X Link 2025-02-19T16:31Z [---] followers, [---] engagements
"I'm playing catch-up after being out of the office for a few days. $HIMS had a mixed Q1 report and shares fell on its light Q2 outlook. $VRTX is also under pressure on a series of setbacks including a pause for its mRNA-based CF drug. $NBIX though saw momentum for Crenessity"
X Link 2025-05-06T16:39Z [---] followers, [---] engagements
"I'm back from a weeklong staycation to celebrate my twins' fifth birthday. The morning kicked off with $IDXX shooting higher on its earnings report. The company is tied to the animal-health space. https://www.investors.com/news/technology/idexx-laboratories-stock-idexx-laboratories-earnings-q2-2025/ https://www.investors.com/news/technology/idexx-laboratories-stock-idexx-laboratories-earnings-q2-2025/"
X Link 2025-08-04T15:38Z [---] followers, [---] engagements
"In earnings news $TGTX beat expectations and raised its outlook but fell on a caveat that undercut its massive profit beat. $IDXX also topped forecasts and shares broke out to a record high. https://www.investors.com/news/technology/idexx-laboratories-idexx-stock-earnings-q3-2025/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q3-2025/ https://www.investors.com/news/technology/idexx-laboratories-idexx-stock-earnings-q3-2025/ https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-earnings-q3-2025/"
X Link 2025-11-03T18:20Z [---] followers, [---] engagements
"$BIOA rocketed after the company reported promising results for its NLRP3 blocker a potential cardiovascular treatment and rival to $LLY takeover play $VTYX. https://www.investors.com/news/technology/bioage-labs-bioage-stock-eli-lilly-ventyx-biosciences-nlrp3/ https://www.investors.com/news/technology/bioage-labs-bioage-stock-eli-lilly-ventyx-biosciences-nlrp3/"
X Link 2026-01-12T18:33Z [---] followers, [---] engagements
"$ISRG disappointed investors earlier this month with its 13%-15% guidance for [----] procedure growth for da Vinci. But an analyst says it's not all gloom for the robotic surgery stock. https://www.investors.com/news/technology/intuitive-surgical-stock-isrg-earnings-q4-2025/ https://www.investors.com/news/technology/intuitive-surgical-stock-isrg-earnings-q4-2025/"
X Link 2026-01-23T17:36Z [---] followers, [---] engagements
"In other earnings news $SNY beat earnings forecasts and Dupixent sales came in ahead though total sales were light. Its key partner $REGN reports tomorrow morning. https://www.investors.com/news/technology/sanofi-stock-sanofi-earnings-q4-2025/ https://www.investors.com/news/technology/sanofi-stock-sanofi-earnings-q4-2025/"
X Link 2026-01-29T21:24Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing